var title_f26_58_27552="Intussusception Air contrast II";
var content_f26_58_27552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Air contrast enema in the same patient showing that the intussusception in mid- transverse colon has been reduced to the ascending colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27552=[""].join("\n");
var outline_f26_58_27552=null;
var title_f26_58_27553="Patient information: Crossed eyes and lazy eye (The Basics)";
var content_f26_58_27553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16726\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/43/4787\">",
"         Crossed eyes (strabismus)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Crossed eyes and lazy eye (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/crossed-eyes-and-lazy-eye-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13653411\">",
"      <span class=\"h1\">",
"       What are crossed eyes and lazy eye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Crossed eyes is a condition in which the eyes don&rsquo;t line up with each other, and don&rsquo;t look in the same direction. The term doctors use for this is &ldquo;strabismus.&rdquo;",
"     </p>",
"     <p>",
"      Lazy eye is a condition in which 1 eye doesn&rsquo;t see as well as the other eye. The term doctors use for this is &ldquo;amblyopia.&rdquo;",
"     </p>",
"     <p>",
"      These conditions happen much more often in children than in adults. Crossed eyes can run in families.",
"     </p>",
"     <p>",
"      If your child has either of these conditions, it&rsquo;s important to get treatment as early as possible. People who don&rsquo;t get these conditions treated in childhood can have life-long vision and eye problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13653426\">",
"      <span class=\"h1\">",
"       What causes these conditions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Crossed eyes is caused by a problem with the muscles that make the eyes move. Different conditions can cause problems with the eye muscles. Some babies are born with crossed eyes.",
"     </p>",
"     <p>",
"      The most common cause of lazy eye is crossed eyes. That&rsquo;s because when someone has crossed eyes, each eye sees and sends a different image to the brain. This is confusing for the brain, so the brain ignores the images from 1 eye. Over time, the ignored eye becomes weaker and doesn&rsquo;t see as well.",
"     </p>",
"     <p>",
"      Other eye problems can also cause lazy eye.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13653441\">",
"      <span class=\"h1\">",
"       What are the symptoms of crossed eyes and lazy eye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people have crossed eyes, their eyes don&rsquo;t line up or move together (",
"      <a class=\"graphic graphic_figure graphicRef74106 \" href=\"UTD.htm?4/43/4787\">",
"       figure 1",
"      </a>",
"      ). This can happen all the time or only sometimes, such as when a person is tired.",
"     </p>",
"     <p>",
"      In lazy eye, the vision in 1 eye is weaker than in the other eye. This can cause double vision and trouble with &ldquo;depth perception&rdquo; (seeing objects as &ldquo;3D&rdquo; instead of flat).",
"     </p>",
"     <p>",
"      These symptoms can be hard to spot, so parents might not notice them. Many times, a child&rsquo;s doctor or nurse first notices these symptoms during a routine check-up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13653456\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your child&rsquo;s doctor or nurse should be able to tell if your child has crossed eyes or lazy eye (or both) by talking with you and doing an exam. During the exam, he or she will check how your child&rsquo;s eyes see and move.",
"     </p>",
"     <p>",
"      The doctor or nurse might have your child see an eye specialist (called an ophthalmologist) for a more detailed eye exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13653471\">",
"      <span class=\"h1\">",
"       How are these conditions treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Helping your child see clearly is the first step in treating both of these conditions. This usually involves having your child wear glasses.",
"     </p>",
"     <p>",
"      Further treatment depends on your child&rsquo;s condition and its cause.",
"     </p>",
"     <p>",
"      Treatment for lazy eye involves making the weaker eye work harder so that it can get stronger. To make the weaker eye work harder, the doctor can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put a patch over your child&rsquo;s stronger eye so that eye can&rsquo;t see",
"       </li>",
"       <li>",
"        Prescribe eye drops for you to put in your child&rsquo;s stronger eye to make the vision in that eye blurry",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment for crossed eyes involves ways to make the eyes line up and work together. The doctor can do this by using special glasses, eye drops, or eye patches.",
"     </p>",
"     <p>",
"      If these treatments don&rsquo;t work, or if your child has severe crossed eyes, he or she might need surgery to fix the eye muscles.",
"     </p>",
"     <p>",
"      After treatment, your child should see the doctor for regular follow-ups. That&rsquo;s because these conditions sometimes come back.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/58/27553?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16726 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27553=[""].join("\n");
var outline_f26_58_27553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13653411\">",
"      What are crossed eyes and lazy eye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13653426\">",
"      What causes these conditions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13653441\">",
"      What are the symptoms of crossed eyes and lazy eye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13653456\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13653471\">",
"      How are these conditions treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/43/4787\">",
"      Crossed eyes (strabismus)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27554="Electron micrograph showing fibronectin glomerulopathy";
var content_f26_58_27554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing fibronectin glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron microscopy of a glomerulus in a patient with fibronectin glomerulopathy. There is mesangial expansion with non-descript electron-dense material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27554=[""].join("\n");
var outline_f26_58_27554=null;
var title_f26_58_27555="Cervicovaginal incision";
var content_f26_58_27555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incision into the anterior vaginal mucosa during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is performed at the level of the cervicovaginal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27555=[""].join("\n");
var outline_f26_58_27555=null;
var title_f26_58_27556="GI vascular development";
var content_f26_58_27556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Development of the gastrointestinal vasculature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Embryo during the sixth week of development, showing blood supply to the segments of the gut and formation and rotation of the primary intestinal loop. The superior mesenteric artery forms the axis of this rotation and supplies the midgut. The celiac and inferior mesenteric arteries supply the foregut and hindgut, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27556=[""].join("\n");
var outline_f26_58_27556=null;
var title_f26_58_27557="Benzocaine: Patient drug information";
var content_f26_58_27557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     see \"Benzocaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"     see \"Benzocaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Americaine&reg; Hemorrhoidal [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Cold Sore Therapy [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Jr. [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; [OTC];",
"     </li>",
"     <li>",
"      Benzodent&reg; [OTC];",
"     </li>",
"     <li>",
"      Bi-Zets [OTC];",
"     </li>",
"     <li>",
"      Boil-Ease&reg; Pain Relieving [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Fizzlers&trade; [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat &amp; Coating [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat Plus Coating Relief [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Ultra Sore Throat [OTC];",
"     </li>",
"     <li>",
"      Chiggerex&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      ChiggerTox&reg; [OTC];",
"     </li>",
"     <li>",
"      Dent's Extra Strength Toothache Gum [OTC];",
"     </li>",
"     <li>",
"      Dentapaine [OTC];",
"     </li>",
"     <li>",
"      Dermoplast&reg; Antibacterial [OTC];",
"     </li>",
"     <li>",
"      Dermoplast&reg; Pain Relieving [OTC];",
"     </li>",
"     <li>",
"      Detane&reg; [OTC];",
"     </li>",
"     <li>",
"      Foille&reg; [OTC];",
"     </li>",
"     <li>",
"      HDA&reg; Toothache [OTC];",
"     </li>",
"     <li>",
"      HurriCaine ONE&trade;;",
"     </li>",
"     <li>",
"      Hurricaine&reg; [OTC];",
"     </li>",
"     <li>",
"      Ivy-Rid&reg; [OTC];",
"     </li>",
"     <li>",
"      Kank-A&reg; Soft Brush [OTC];",
"     </li>",
"     <li>",
"      Lanacane&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Lanacane&reg; [OTC];",
"     </li>",
"     <li>",
"      Little Teethers&reg; [OTC];",
"     </li>",
"     <li>",
"      Medicone&reg; Hemorrhoidal [OTC];",
"     </li>",
"     <li>",
"      Mycinettes&reg; [OTC];",
"     </li>",
"     <li>",
"      Orabase&reg; with Benzocaine [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Daytime and Nighttime [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Teething Nighttime [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Teething [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Cold Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Denture Plus [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Medicated Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Medicated Toothache [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Multi-Action Cold Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; PM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Ultra Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; [OTC];",
"     </li>",
"     <li>",
"      Outgro&reg; [OTC];",
"     </li>",
"     <li>",
"      Red Cross&trade; Canker Sore [OTC];",
"     </li>",
"     <li>",
"      Rid-A-Pain Dental [OTC];",
"     </li>",
"     <li>",
"      Sepasoothe&reg; [OTC];",
"     </li>",
"     <li>",
"      Skeeter Stik&reg; [OTC];",
"     </li>",
"     <li>",
"      Sore Throat Relief [OTC];",
"     </li>",
"     <li>",
"      Sting-Kill&reg; [OTC];",
"     </li>",
"     <li>",
"      Tanac&reg; [OTC];",
"     </li>",
"     <li>",
"      Thorets [OTC];",
"     </li>",
"     <li>",
"      Trocaine&reg; [OTC];",
"     </li>",
"     <li>",
"      Zilactin&reg; Tooth &amp; Gum Pain [OTC];",
"     </li>",
"     <li>",
"      Zilactin&reg;-B [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anbesol&reg; Baby;",
"     </li>",
"     <li>",
"      Zilactin Baby&reg;;",
"     </li>",
"     <li>",
"      Zilactin-B&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat signs of hemorrhoids or rectal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease the pain caused by sunburn and skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain from a toothache, sore throat, or canker sore.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzocaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a skin infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you smoke, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blue or gray skin color, headache, dizziness, trouble breathing, feeling tired or weak, and/or a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using the spray for your face, spray it on your hand or gauze and then put it on your face.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11585 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27557=[""].join("\n");
var outline_f26_58_27557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139882\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012253\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012252\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012257\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012258\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012260\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012255\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012256\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012261\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012262\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=related_link\">",
"      Benzocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=related_link\">",
"      Benzocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27558="Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis";
var content_f26_58_27558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Madhura Tamhankar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Nicholas J Volpe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27558/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/58/27558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic optic neuropathy is the most common optic nerve disorder in patients over age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/1\">",
"     1",
"    </a>",
"    ]. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar) and as arteritic versus nonarteritic. Anterior involvement is common with both arteritic and nonarteritic ischemic optic neuropathy.",
"   </p>",
"   <p>",
"    Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical features, and diagnosis of NAION. The epidemiology, pathogenesis, etiologies, prognosis, and treatment of NAION are discussed separately. Other forms of ischemic optic neuropathy and other optic neuropathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=see_link\">",
"     \"Nonarteritic ischemic optic neuropathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients describe a sudden onset of monocular vision loss or visual field loss. This is often noticed upon awakening, in as many as 73 percent of patients in some reports, although in the Ischemic Optic Neuropathy Decompression Trial (IONDT) symptoms first present on awakening were reported in just 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The vision loss is typically reported as diffuse blurring or cloudiness in the affected eye; some patients may report altitudinal loss or a scotoma. It is common for visual loss to progress over the first few days; in one study the average time to peak vision loss was about five days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/4\">",
"     4",
"    </a>",
"    ]. Most patients stabilize in one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is rare for the symptoms to occur in both eyes at the same time. In one series, 11 percent had a bilateral presentation, but most of these cases occurred in the setting of severe blood pressure fluctuations (eg, surgery, dialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prodromal ocular or systemic symptoms are atypical for NAION and suggest an alternative etiology such as giant cell arteritis. However, in the IONDT, five percent reported that their symptoms were intermittent at onset [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain is not typical, but some ocular discomfort has been reported in 8 to 12 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2,4,7\">",
"     2,4,7",
"    </a>",
"    ]. If pain is a prominent complaint, NAION is less likely to be the diagnosis than optic neuritis or giant cell arteritis (arteritic ischemic optic neuropathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of patients with NAION typically reveals:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced visual acuity",
"     </li>",
"     <li>",
"      Dyschromatopsia",
"     </li>",
"     <li>",
"      Afferent pupillary defect",
"     </li>",
"     <li>",
"      Optic disc edema (",
"      <a class=\"graphic graphic_picture graphicRef58158 \" href=\"UTD.htm?39/24/40335\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Peripapillary splinter hemorrhage",
"     </li>",
"     <li>",
"      Small optic cup, nerve fiber crowding in the unaffected eye (",
"      <a class=\"graphic graphic_picture graphicRef64959 \" href=\"UTD.htm?27/3/27696\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An entity of so-called incipient NAION has been described in patients who are found on examination to have unilateral optic disc edema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Such patients are typically seen in follow-up after a previous episode of NAION in the other eye or for unrelated conditions (eg, diabetic retinopathy). In one series, 25 percent of such patients progressed to symptomatic NAION over a few to several weeks, and a subsequent episode of NAION in that eye occurred in an additional 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relative afferent pupillary defect is an invariable manifestation of NAION, as with other optic neuropathies. However, the finding may be subtle if the injury is not severe or if there was previous NAION in the other eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Optic disc appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to giant cell arteritis, the optic disc edema in NAION tends to be hyperemic (",
"    <a class=\"graphic graphic_picture graphicRef58158 \" href=\"UTD.htm?39/24/40335\">",
"     picture 1",
"    </a>",
"    ) rather than pallid (",
"    <a class=\"graphic graphic_picture graphicRef69437 \" href=\"UTD.htm?12/32/12815\">",
"     picture 3",
"    </a>",
"    ). In the IONDT, optic nerve head swelling was diffuse in 75 percent and segmental in 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2\">",
"     2",
"    </a>",
"    ]. Segmental disc edema usually involves the superior portion of the disc; this anatomic distribution has been attributed to the anatomic division of the circle of Zinn-Haller. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Vascular anatomy'",
"    </a>",
"    .) Segmental disc edema may not correspond to distribution of vision loss.",
"   </p>",
"   <p>",
"    Disc hyperemia with splinter or flame hemorrhages and dilated telangiectatic capillaries is common and was seen in 72 percent of patients in IONDT (",
"    <a class=\"graphic graphic_picture graphicRef58158 \" href=\"UTD.htm?39/24/40335\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2\">",
"     2",
"    </a>",
"    ]. These features may represent microvascular shunting from ischemic to nonischemic regions of the optic nerve head. The retinal arterioles are typically narrowed focally in the peripapillary region in up to 68 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fellow eye will often reveal a crowded optic nerve head with small or absent physiologic cup (",
"    <a class=\"graphic graphic_picture graphicRef64959 \" href=\"UTD.htm?27/3/27696\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. This disk appearance has been denoted the \"disk at risk\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Ocular risk factors'",
"    </a>",
"    .) In one case series, this finding was noted in 82 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/6\">",
"     6",
"    </a>",
"    ]. Alternatively, the fellow eye may demonstrate optic disc pallor that suggests a prior episode of NAION; in the IONDT, 94 of 420 patients (23 percent) had this finding; 61 of these patients reported a known history of NAION in that eye [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vision loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual acuity loss in NAION is on average less severe than in arteritic ischemic optic neuropathy, but can range from",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    to no light perception, depending upon the area of optic nerve head involved. Visual acuity is better than",
"    <span class=\"nowrap\">",
"     20/60",
"    </span>",
"    in 31 to 52 percent of patients, and is better than",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    in one-half to two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/1,2,4,5,15,16\">",
"     1,2,4,5,15,16",
"    </a>",
"    ]. Some patients with NAION may have normal visual acuity",
"    <span class=\"nowrap\">",
"     (20/20",
"    </span>",
"    or better) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Color vision is diminished in almost all patients in the affected eye. The color vision loss seems to correlate with the degree of vision loss. In contrast, patients with optic neuritis may have profound color vision loss with relatively good visual recovery.",
"   </p>",
"   <p>",
"    An altitudinal visual field defect is the classically described field defect seen in NAION, but among reported case series, its prevalence varies from 25 to 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ]. In one series of perimetry studies in 312 eyes, a variety of visual field defects were observed, with an absolute inferior altitudinal defect observed in only 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/18\">",
"     18",
"    </a>",
"    ]. The single most commonly observed defect was an absolute inferior nasal defect, found in 22 percent. Other common defects included central, centrocecal and arcuate scotomas, as well as generalized depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major alternative diagnosis is giant cell arteritis or arteritic anterior ischemic optic neuropathy. This also primarily affects older adults, usually over the age of 70 years, and the clinical presentation can be similar. One distinguishing feature of giant cell arteritis is a prodrome of systemic symptoms known as polymyalgia rheumatica, which include jaw claudication, proximal myalgias and arthralgias, scalp tenderness, headache, and fatigue. Disc edema tends to be pallid rather than hyperemic (",
"    <a class=\"graphic graphic_picture graphicRef58158 \" href=\"UTD.htm?39/24/40335\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69437 \" href=\"UTD.htm?12/32/12815\">",
"     picture 3",
"    </a>",
"    ); and transient prodromal vision loss is more common in giant cell arteritis than in NAION. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optic neuritis can also present with acute monocular vision loss with disc edema. In comparison to NAION, patients tend to be younger (usually 18 to 40 years) and pain is usually a prominent feature.",
"   </p>",
"   <p>",
"    There are numerous other causes of optic nerve disease (",
"    <a class=\"graphic graphic_table graphicRef75945 \" href=\"UTD.htm?20/31/20988\">",
"     table 1",
"    </a>",
"    ). Some of the clinical features of the more common disorders are contrasted in the Table (",
"    <a class=\"graphic graphic_table graphicRef51786 \" href=\"UTD.htm?42/48/43788\">",
"     table 2",
"    </a>",
"    ); these are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NAION in the majority of patients is clinical, based upon age, presence of vasculopathic risk factors, the pattern of visual loss, and the appearance of the swollen disc.",
"   </p>",
"   <p>",
"    The major diagnostic consideration in anterior ischemic optic neuropathy is differentiating arteritic (eg, giant cell arteritis) from nonarteritic ischemic optic neuropathy. Elderly patients with anterior ischemic optic neuropathy should be questioned regarding headache, scalp tenderness, and jaw claudication for giant cell arteritis. In patients older than 55 years an erythrocyte sedimentation rate (ESR) and C-reactive protein levels are obtained. Temporal artery biopsy should be considered if these are abnormal or if there is a high clinical suspicion for giant cell arteritis because of suggestive symptoms such as headache or jaw claudication (",
"    <a class=\"graphic graphic_table graphicRef51786 \" href=\"UTD.htm?42/48/43788\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, no other testing is required for patients with typical features of NAION. The following features are atypical and suggest the need for further testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age less than 50 years",
"     </li>",
"     <li>",
"      Absence of vasculopathic risk factors",
"     </li>",
"     <li>",
"      Large cup to disc ratio in the unaffected eye",
"     </li>",
"     <li>",
"      Hemianopic visual field loss",
"     </li>",
"     <li>",
"      Bilateral simultaneous or rapidly sequential anterior ischemic optic neuropathy",
"     </li>",
"     <li>",
"      Transient visual loss preceding visual loss",
"     </li>",
"     <li>",
"      No optic disc edema in acute phase",
"     </li>",
"     <li>",
"      Progression after two to four weeks",
"     </li>",
"     <li>",
"      Recurrence in same eye",
"     </li>",
"     <li>",
"      Inflammation in anterior or posterior segment",
"     </li>",
"     <li>",
"      Optic atrophy at presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further testing in such patients may include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography.",
"   </p>",
"   <p>",
"    In the acute phase of NAION there is delayed filling of the prelaminar layers of the edematous optic disc [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Poor or absent filling of the choroid is not typical of NAION and suggests giant cell arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast-enhanced magnetic resonance imaging (MRI) may be useful in younger patients to differentiate NAION and optic neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ]. While 95 percent of patients with optic neuritis will demonstrate gadolinium contrast enhancement of the optic nerve, this is relatively unusual (&lt;10 percent) in NAION. MRI is also useful to evaluate for compressive and infiltrative optic neuropathies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Generally, carotid Doppler studies and cardiac echocardiography are not indicated for NAION, since embolism is not causative in the vast majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/25\">",
"     25",
"    </a>",
"    ]. MRI and MR angiography of the cervical carotid artery may be considered to rule out carotid dissection if there is neck pain, antecedent trauma, or other suggestive features of this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H4#H4\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of 24-hour blood pressure may identify individuals with nocturnal hypotension (believed to be a risk factor for NAION), but limited treatment options are available for patients at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Nocturnal hypotension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercoagulable studies are generally recommended only if there is a past medical or family history suggesting a thrombogenic tendency, but they should also be considered in young patients (&lt; 55 years) without vascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27558/abstract/6,27-30\">",
"     6,27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H8#H8\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Prothrombotic risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically order polysomnography to evaluate for sleep apnea in patients with NAION who endorse symptoms of daytime sleepiness, have night-time snoring,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are obese.",
"   </p>",
"   <p>",
"    Orbital ultrasound may identify optic disc drusen in patients without other risk factors for ischemic optic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Ocular risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common cause of optic neuropathy in older adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typical presentation is sudden onset of painless monocular vision loss, often upon awakening. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination findings include optic disc edema, reduced visual acuity (which is often mildly better than",
"      <span class=\"nowrap\">",
"       20/60),",
"      </span>",
"      and an afferent pupillary defect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small optic cup is usually seen in the fellow eye and has been termed the \"disc at risk\". (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Optic disc appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In individuals older than 70 years, the major alternative diagnostic consideration is giant cell arteritis. Unlike NAION, arteritic ischemic optic neuropathy usually occurs in the setting of polymyalgia rheumatica. All patients over 70 years with ischemic optic neuropathy should have screening blood tests for giant cell arteritis, and further testing if these are abnormal or if the clinical setting is suspicious. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an older individual (&gt;50 years) with typical clinical features of NAION, further testing beyond screening blood tests for GCA is not required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In young patients (&lt;50 years), optic neuritis should be considered as an alternate diagnosis. Contrast-enhanced brain magnetic resonance imaging study demonstrates optic nerve enhancement in most cases of optic neuritis, but very few patients with NAION. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with other atypical features of NAION should also undergo further testing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"       \"Optic neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/1\">",
"      Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/2\">",
"      Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/3\">",
"      Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol 1997; 124:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/4\">",
"      Rizzo JF 3rd, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 1991; 109:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/5\">",
"      Boghen DR, Glaser JS. Ischaemic optic neuropathy. The clinical profile and history. Brain 1975; 98:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/6\">",
"      Preechawat P, Bruce BB, Newman NJ, Biousse V. Anterior ischemic optic neuropathy in patients younger than 50 years. Am J Ophthalmol 2007; 144:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/7\">",
"      Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 1995; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/8\">",
"      Hayreh SS, Zimmerman MB. Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2007; 114:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/9\">",
"      Prenner JL, Sharma A, Ibarra MS, et al. Prolonged premonitory optic disc signs in anterior ischemic optic neuropathy. J Neuroophthalmol 2002; 22:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/10\">",
"      Rader J, Feuer WJ, Anderson DR. Peripapillary vasoconstriction in the glaucomas and the anterior ischemic optic neuropathies. Am J Ophthalmol 1994; 117:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/11\">",
"      Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol 1981; 38:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/12\">",
"      Feit RH, Tomsak RL, Ellenberger C Jr. Structural factors in the pathogenesis of ischemic optic neuropathy. Am J Ophthalmol 1984; 98:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/13\">",
"      Beck RW, Savino PJ, Repka MX, et al. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology 1984; 91:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/14\">",
"      Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropathy. Arch Ophthalmol 1985; 103:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/15\">",
"      Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983; 96:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/16\">",
"      Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/17\">",
"      Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 2008; 115:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/18\">",
"      Hayreh SS, Zimmerman B. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Arch Ophthalmol 2005; 123:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/19\">",
"      Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/20\">",
"      Lee AG, Lin DJ, Kaufman M, et al. Atypical features prompting neuroimaging in acute optic neuropathy in adults. Can J Ophthalmol 2000; 35:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/21\">",
"      Arnold AC, Hepler RS. Natural history of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 1994; 14:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/22\">",
"      Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 117:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/23\">",
"      Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/24\">",
"      Gass A, Moseley IF. The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage. J Neurol Sci 2000; 172 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/25\">",
"      Fry CL, Carter JE, Kanter MC, et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 1993; 24:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/26\">",
"      Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/27\">",
"      Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/28\">",
"      Feldon SE. Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology 1999; 106:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/29\">",
"      Biousse V. Coagulation abnormalities and their neuro-ophthalmologic manifestations. Curr Opin Ophthalmol 1999; 10:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27558/abstract/30\">",
"      Kuhli-Hattenbach C, Scharrer I, L&uuml;chtenberg M, Hattenbach LO. Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2009; 247:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5256 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27558=[""].join("\n");
var outline_f26_58_27558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Optic disc appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vision loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5256|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/24/40335\" title=\"picture 1\">",
"      Acute NAION fundus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/3/27696\" title=\"picture 2\">",
"      Asymptomatic eye NAION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/32/12815\" title=\"picture 3\">",
"      Giant cell arteritis fundus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/31/20988\" title=\"table 1\">",
"      Causes of optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/48/43788\" title=\"table 2\">",
"      Clinical features of common optic neuropathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=related_link\">",
"      Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27559="Pyruvate kinase deficiency";
var content_f26_58_27559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyruvate kinase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Josef T Prchal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27559/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/58/27559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate kinase (PK) deficiency is the most common cause of congenital non-spherocytic chronic hemolytic anemia and is the result of an erythrocyte enzyme defect. It is an autosomal recessive condition caused by a deficiency of erythrocytic PK. Although the gene frequency for PK deficiency is lower than that for glucose-6-phosphate dehydrogenase (G6PD) deficiency, the vast majority of patients inheriting G6PD deficiency never suffer acute or chronic hemolysis, whereas chronic hemolysis of variable severity is common in those with PK deficiency.",
"   </p>",
"   <p>",
"    The molecular biology, clinical presentation, diagnosis, and treatment of PK deficiency are reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/1\">",
"     1",
"    </a>",
"    ]. An approach to the patient with suspected hemolytic anemia and an overview of the congenital hemolytic anemias in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate kinase (PK) enzymes consist of several isoforms; they are products of two distinct M and LR",
"    <em>",
"     PK",
"    </em>",
"    genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The M (muscle) gene is expressed in muscle, brain, white cells, and platelets; it is located on chromosome 15q22. The M1 and M2 isoforms are the result of a differential processing of this single gene transcript. The M2 isoform is the dominant fetal form, and it is replaced after birth largely by the M1 isoform. The M2 isoform persists in adult life in white cells and platelets. In erythroid progenitors, it is progressively replaced by the R form.",
"     </li>",
"     <li>",
"      The L (liver) and R (red cell) isoenzymes are encoded by the LR gene on chromosome 1q21; these isoforms vary because of a differential use of tissue-specific promoters, as well as different exons at the 5' coding region. The R form, unique to erythrocytes, is 33 amino acids larger than the L form, which is unique to hepatocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical PK deficiency with hemolytic anemia is limited to mutations of the LR gene. Accordingly, in affected individuals, activity of erythrocytic PK is reduced markedly, whereas PK activity in white cells, platelets, and other tissues is normal.",
"   </p>",
"   <p>",
"    The complexity of PK isoforms is accentuated by the fact that the functional enzyme is a tetramer. As an example, in patients heterozygous for two different PK mutations, five different tetramers will be present (eg, tetramers containing zero, 25, 50, 75, and 100 percent of each of the two mutant protein chains).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;PK, an allosteric enzyme involved in the intermediary metabolism of glucose, has one binding site for its substrate, phosphoenol pyruvate (PEP), which it converts enzymatically to pyruvate. The energy gained in this reaction is employed to add inorganic phosphorus to adenosine diphosphate (ADP) to form the high energy compound adenosine triphosphate (ATP) (",
"    <a class=\"graphic graphic_figure graphicRef83968 \" href=\"UTD.htm?12/33/12830\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pyruvate kinase interacts with the metabolic intermediate fructose 1,6-diphosphate (FDP), which changes the conformational structure of PK, decreasing the Michaelis constant (Km) of PK for its substrate PEP, dramatically increasing its enzymatic activity (Vmax). Mutations of PK may involve any of the following properties of the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered affinity for its substrate, PEP",
"     </li>",
"     <li>",
"      Altered affinity for its allosteric activator, FDP",
"     </li>",
"     <li>",
"      Altered enzymatic stability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism for hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism for hemolysis in PK deficiency is not clear. Although the defect in ATP generation contributes to hemolysis, it is not a sufficient explanation because ATP deficiency is difficult to demonstrate in some of the affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, other disorders with more severe degrees of ATP deficiency are not associated with significant hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/4\">",
"     4",
"    </a>",
"    ]. It has been alleged that the mechanism of hemolysis in PK deficiency is similar to the as yet unexplained destruction of young red cells described in individuals descending from high altitude, a process termed &ldquo;neocytolysis&rdquo;; however this remains speculative at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hemolytic anemia who undergo splenectomy, with a resultant decrease in the hemolytic process and improvement of anemia, have a higher number of reticulocytes than they did before the splenectomy. This perplexing observation indicates that our knowledge of the regulation of erythropoiesis and reticulocyte kinetics remains incomplete. A significant interaction may occur between the spleen and PK-deficient young red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/6\">",
"     6",
"    </a>",
"    ], through an as yet unknown mechanism, which influences premature destruction of reticulocytes and young red cells in this organ, especially in patients with significant degrees of PK deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolic disturbances in PK deficiency affect not only the survival of red cells but also the maturation of splenic erythroid progenitors, which results in their apoptosis. This has been demonstrated in a splenectomized PK deficient patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/10\">",
"     10",
"    </a>",
"    ] as well as in a PK deficient mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/11\">",
"     11",
"    </a>",
"    ]. It remains to be established, however, whether apoptosis of erythroid progenitors in PK deficiency extends to marrow erythroblasts, if this observation accounts for the previously unexplained post-splenectomy reticulocytosis, and if PK activity has any role in the apoptotic pathway in general [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the severity of the disease is related to two separate factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disruptive effect of the",
"      <em>",
"       PK",
"      </em>",
"      LR gene mutation(s)",
"     </li>",
"     <li>",
"      Compensatory expression of the M2 isozyme in erythrocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8012941\">",
"    <span class=\"h2\">",
"     Compensatory increase in oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The block in glycolysis in PK deficiency is downstream of the Rappaport-Luebering shunt, in which the metabolic intermediate, 2,3-bisphosphoglycerate (2,3-BPG) is formed. An accumulation of 2,3-BPG has been noted in PK deficiency, in contrast to a low concentration in hexokinase deficiency, which is upstream from the shunt. This leads to a \"rightward\" shift of the oxygen dissociation curve for hemoglobin in patients with PK deficiency, resulting in better oxygen delivery to the tissues and superior tolerance for anemia, in comparison to patients with defects upstream to the Rappaport-Luebering shunt, such as hexokinase deficiency (",
"    <a class=\"graphic graphic_figure graphicRef83968 \" href=\"UTD.htm?12/33/12830\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H9#H9\">",
"     \"Structure and function of normal human hemoglobins\", section on '2,3-bisphosphoglycerate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate kinase deficiency is an autosomal recessive disorder; affected individuals are either homozygous for a single mutation or doubly heterozygous for two different PK mutations. Subjects who are heterozygous for PK deficiency have intermediate enzyme levels and are not affected clinically.",
"   </p>",
"   <p>",
"    The PK phenotype has a worldwide distribution, but is more common among people of northern European extraction and perhaps Chinese [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/14\">",
"     14",
"    </a>",
"    ]. In these populations the frequency of heterozygosity may exceed 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/15\">",
"     15",
"    </a>",
"    ]. As with any autosomal recessive disorder, PK deficiency can be more common in groups with a history of inbreeding or consanguinity. As an example, a high frequency of this disorder has been documented among Pennsylvania Amish [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/16\">",
"     16",
"    </a>",
"    ]. In such isolated populations, a \"founder\" effect can be implicated readily.",
"   </p>",
"   <p>",
"    Over 158 mutations and eight polymorphic sites have been reported on the",
"    <em>",
"     PK",
"    </em>",
"    LR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. Single nucleotide substitutions have been described, as have intronic and exonic deletions and insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The 1529A mutation is especially common, even among unrelated families [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on the gene frequency of the 1529A mutation in the white population and on its relative abundance in patients with hemolytic anemia, the prevalence of PK deficiency is estimated at 51 cases per million white population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/21\">",
"     21",
"    </a>",
"    ]. PK deficiency has also been described in an inbred mouse strain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/22\">",
"     22",
"    </a>",
"    ] and in the Basenji dog [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;PK deficiency is associated with protection against malaria in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/24\">",
"     24",
"    </a>",
"    ]. Although there is no indication of a positive selection pressure in the geographic distribution of PK deficiency in humans, in vitro experiments have shown the following two protective effects against P. falciparum in the red cells of individuals with PK deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced invasion of erythrocytes in homozygotes",
"     </li>",
"     <li>",
"      Preferential macrophage clearance of ring-stage-infected RBCs in both homozygotes and heterozygotes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of hemolysis in PK-deficient patients is highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/26\">",
"     26",
"    </a>",
"    ]. It may be the cause of death in utero from non-immune hydrops fetalis or death shortly after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/27\">",
"     27",
"    </a>",
"    ]. However, more commonly, the disorder ranges from a life-threatening transfusion-requiring hemolytic anemia present since birth to a mild, fully compensated hemolytic process.",
"   </p>",
"   <p>",
"    However, a similar degree of severity of disease is typical for affected individuals within a family in which multiple members have the identical genetic defect. The disease has been reported to be particularly severe among the Amish of Pennsylvania, with occasional lethal outcomes in children unless splenectomy is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PK deficiency and severe hemolysis usually present with pallor, icterus, and splenomegaly, and develop the clinical complications typical of chronic hemolytic states. These include the following. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatosplenomegaly of varying degree",
"     </li>",
"     <li>",
"      Pigmented (bilirubin) gallstones",
"     </li>",
"     <li>",
"      Worsening anemia secondary to transient aplastic anemia caused by infection (eg, parvovirus) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H10#H10\">",
"       \"Anemia in children due to decreased red blood cell production\", section on 'Acquired pure red cell aplasia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      deficiency secondary to increased requirements",
"     </li>",
"     <li>",
"      Skin ulcers",
"     </li>",
"     <li>",
"      Clinically significant iron overload, especially in those requiring multiple transfusions",
"     </li>",
"     <li>",
"      Worsening hemolysis during pregnancy and after use of oral contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with pyruvate kinase deficiency uniformly have evidence for increased red blood cell destruction, including elevated levels of indirect bilirubin, increased polychromasia on the blood smear, and reticulocytosis (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"UTD.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    ). Hemolysis is mainly extravascular; however, elevation of serum lactate dehydrogenase (LDH) and reduced levels of haptoglobin may be variably seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the peripheral smear most often demonstrates only nonspecific morphologic abnormalities; contracted echinocytes (contracted burr cells) have been described in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Of interest, spiculated red cells have also been noted in the peripheral smear of Basenji dogs with PK deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link&amp;anchor=H17#H17\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\", section on 'Hematologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No laboratory measurement, other than assay of erythrocytic PK enzymatic activity, is helpful in arriving at an appropriate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/33\">",
"     33",
"    </a>",
"    ]. High levels of the glycolytic intermediates 2,3-BPG and 3-phosphoglyceric acid (3-PG) are common occurrences in PK deficiency. A review of results in 52 families with this disorder indicated that a rise in 3-PG is a valuable indicator of PK deficiency, although this test is not generally available outside of a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike congenital spherocytic hemolytic anemias, osmotic fragility of the patient's red blood cells is normal. The autohemolysis test, in which hemolysis is evaluated in vitro in the presence or absence of added glucose, lacks physiologic relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/35\">",
"     35",
"    </a>",
"    ] and should not be employed.",
"   </p>",
"   <p>",
"    Several screening tests have been employed with some clinical utility. These detect most, but not all, mutant variants. Some of the PK mutations interfering with the interaction between PK and FDP or those mutations with an increased Km for substrate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/33\">",
"     33",
"    </a>",
"    ] may not be detected by generally available tests for PK deficiency. Routine commercial laboratories typically cannot perform the appropriate quantitative analyses with varying concentrations of substrate (ie, to screen for high Km mutants) and with or without FDP (ie, to screen for mutants with altered allosteric interaction with FDP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6454714\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pyruvate kinase (PK) deficiency is made when the following two criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical and laboratory evidence for hemolytic anemia",
"     </li>",
"     <li>",
"      Low levels of erythrocytic PK enzymatic activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mutant PK enzyme also may be analyzed via kinetic and electrophoretic studies of the partially purified enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/36\">",
"     36",
"    </a>",
"    ]. However, these approaches have been largely replaced by the detection of mutations at the cDNA or genomic level [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/37\">",
"     37",
"    </a>",
"    ]. These latter tests also allow for prenatal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major condition(s) to be distinguished from PK deficiency include the congenital, nonspherocytic hemolytic anemias (ie, intrinsic red blood cell defects, (",
"    <a class=\"graphic graphic_table graphicRef72394 \" href=\"UTD.htm?20/27/20924\">",
"     table 1",
"    </a>",
"    )). These primarily include deficiency of enzymes in the glycolytic and glutathione pathways.",
"   </p>",
"   <p>",
"    In general, enzyme deficiencies within the glycolytic pathway (eg, PK deficiency, hexokinase deficiency) differ from deficiencies within the glutathione pathway (eg, G6PD deficiency, glutathione synthase deficiency) in several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They are not subject to hemolysis after exposure to oxidant agents.",
"     </li>",
"     <li>",
"      The mechanism of hemolysis is not clearly understood.",
"     </li>",
"     <li>",
"      There are no characteristic morphologic red cell abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical phenotype of each of these disorders differs and is not predictable; the phenotype appears to be specific for each enzymatic defect. Accurate diagnosis of these disorders requires the quantitation of enzyme activity in a hemolysate prepared from white blood cell- and platelet-depleted washed red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PK deficiency depends upon the time when the disorder becomes evident. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe anemia with fetal hydrops may require intrauterine transfusion.",
"     </li>",
"     <li>",
"      Hyperbilirubinemia during the neonatal period may necessitate phototherapy or exchange transfusion.",
"     </li>",
"     <li>",
"      Severe disease may require frequent red cell transfusions throughout infancy and into adulthood. The degree of hemolytic anemia is, however, always reduced following splenectomy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Splenectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with extremely severe disease who continue to be transfusion-dependent after splenectomy, allogeneic hematopoietic cell transplantation may be considered (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids are of no value in this condition. Drugs with oxidant potential appear to be safely employed in this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload, with its attendant complications, often requiring iron chelation therapy, has been documented in occasional non-transfused patients with PK deficiency, some of whom were shown to have concomitant hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/40-42\">",
"     40-42",
"    </a>",
"    ] or reduced levels of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/43\">",
"     43",
"    </a>",
"    ]. Accordingly, treatment with iron is contraindicated unless documented iron deficiency is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial effect of splenectomy on hemolysis has been well documented. Typically, hemolysis and anemia are ameliorated but not entirely abated. In severe cases the transfusion requirement is generally, but not invariably, abolished. No reliable way to predict success of splenectomy exists. However, results of splenectomy in other family members may be of major guidance in this matter. Concomitant splenectomy should be strongly encouraged if the patient requires surgery for removal of pigment (bilirubin) gallstones; these procedures can at times be performed simultaneously using laparoscopic techniques.",
"   </p>",
"   <p>",
"    Even if the affected infant is transfusion-dependent, delaying splenectomy as long as possible is advisable, preferably after the age of three years, since the immune suppressive effect and high susceptibility to infectious agents following splenectomy declines after that age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .) A single report indicates failure of",
"    <strong>",
"     partial",
"    </strong>",
"    splenectomy (80 percent) to reduce the transfusion requirement of a four-year-old patient with PK deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/44\">",
"     44",
"    </a>",
"    ]. Six months later, she successfully underwent total splenectomy and became transfusion-independent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Folic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased red blood cell turnover in this and other chronic hemolytic disorders may lead to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency. Although folic acid replacement is frequently employed, it may not always be necessary, especially in those with mild hemolysis. However, folic acid is inexpensive and safe, and has no contraindications in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful hematopoietic cell transplantation has been described in a five-year-old boy with severe PK deficiency (eg, neonatal jaundice and severe transfusion-dependent hemolytic anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gene transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barriers to gene therapy in humans are formidable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10969?source=see_link&amp;anchor=H5#H5\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\", section on 'Gene transfer into stem cells'",
"    </a>",
"    .) However, the human",
"    <em>",
"     PK",
"    </em>",
"    LR gene has been successfully transferred into leukemic cell lines and murine stem cells via retroviral transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27559/abstract/45\">",
"     45",
"    </a>",
"    ]. The human gene product has been detected in lethally irradiated mice transplanted with these transduced murine stem cells as long as 135 days after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13916755\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyruvate kinase (PK) deficiency is the most common cause of congenital non-spherocytic chronic hemolytic anemia. It is an autosomal recessive condition caused by a deficiency of erythrocytic PK. The mechanism for hemolysis in PK deficiency is not clear. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mechanism for hemolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of hemolysis in PK-deficient patients is highly variable, ranging from a life-threatening transfusion-requiring hemolytic anemia present since birth to a fully compensated hemolytic process. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests are consistent with the presence of extravascular hemolysis with a brisk reticulocyte response. Assay of erythrocytic PK enzymatic activity is required for making a specific diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of PK deficiency depends upon the time when the disorder becomes evident. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intrauterine transfusion is indicated in affected fetuses with severe anemia and fetal hydrops. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link&amp;anchor=H7#H7\">",
"       \"Intrauterine fetal transfusion of red blood cells\", section on 'Inherited RBC disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phototherapy with or without exchange transfusion is indicated for severe hyperbilirubinemia during the neonatal period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Phototherapy indications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Exchange transfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients requiring chronic or intermittent transfusions, clinically significant iron overload is frequent and chelation therapy may be necessary.",
"     </li>",
"     <li>",
"      As a general precaution, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be given prophylactically to avoid the development of folic acid deficiency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Folic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatment is needed if hemolysis is fully compensated (ie, minimal or no anemia) in infants and adults. In those with severe, symptomatic anemia, splenectomy is an option for reducing symptoms and the frequency of red cell transfusions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with extremely severe disease who have not benefitted from splenectomy, hematopoietic cell transplantation is an option. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/1\">",
"      Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 2005; 130:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/2\">",
"      Wang C, Chiarelli LR, Bianchi P, et al. Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 2001; 98:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/3\">",
"      Valentine WN, Paglia DE. The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: a viewpoint. Blood Cells 1980; 6:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/4\">",
"      Beutler E. The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: \"A viewpoint\". A commentary. Blood Cells 1980; 6:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/5\">",
"      Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005; 15:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/6\">",
"      Oski FA, Marshall BE, Cohen PJ, et al. The role of the left-shifted or right-shifted oxygen-hemoglobin equilibrium curve. Ann Intern Med 1971; 74:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/7\">",
"      Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: physiological down-regulator of red-cell mass. Lancet 1997; 349:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/8\">",
"      Nathan DG, Oski FA, Miller DR, Gardner FH. Life-span and organ sequestration of the red cells in pyruvate kinase deficiency. N Engl J Med 1968; 278:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/9\">",
"      Mentzer WC Jr, Baehner RL, Schmidt-Sch&ouml;nbein H, et al. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest 1971; 50:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/10\">",
"      Aizawa S, Kohdera U, Hiramoto M, et al. Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. Am J Hematol 2003; 74:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/11\">",
"      Aizawa S, Harada T, Kanbe E, et al. Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity. Exp Hematol 2005; 33:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/12\">",
"      Shimizu T, Uehara T, Nomura Y. Possible involvement of pyruvate kinase in acquisition of tolerance to hypoxic stress in glial cells. J Neurochem 2004; 91:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/13\">",
"      Diez A, Gilsanz F, Martinez J, et al. Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. Blood 2005; 106:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/14\">",
"      Fung RH, Keung YK, Chung GS. Screening of pyruvate kinase deficiency and G6PD deficiency in Chinese newborn in Hong Kong. Arch Dis Child 1969; 44:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/15\">",
"      Mohrenweiser HW. Functional hemizygosity in the human genome: direct estimate from twelve erythrocyte enzyme loci. Hum Genet 1987; 77:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/16\">",
"      BOWMAN HS, MCKUSICK VA, DRONAMRAJU KR. PYRUVATE KINASE DEFICIENT HEMOLYTIC ANEMIA IN AN AMISH ISOLATE. Am J Hum Genet 1965; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/17\">",
"      Pissard S, Max-Audit I, Skopinski L, et al. Pyruvate kinase deficiency in France: a 3-year study reveals 27 new mutations. Br J Haematol 2006; 133:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/18\">",
"      Neubauer B, Lakomek M, Winkler H, et al. Point mutations in the L-type pyruvate kinase gene of two children with hemolytic anemia caused by pyruvate kinase deficiency. Blood 1991; 77:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/19\">",
"      Zanella A, Bianchi P, Fermo E, et al. Molecular characterization of the PK-LR gene in sixteen pyruvate kinase-deficient patients. Br J Haematol 2001; 113:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/20\">",
"      Kanno H, Fujii H, Hirono A, et al. Identical point mutations of the R-type pyruvate kinase (PK) cDNA found in unrelated PK variants associated with hereditary hemolytic anemia. Blood 1992; 79:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/21\">",
"      Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 2000; 95:3585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/22\">",
"      Morimoto M, Kanno H, Asai H, et al. Pyruvate kinase deficiency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Blood 1995; 86:4323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/23\">",
"      Whitney KM, Goodman SA, Bailey EM, Lothrop CD Jr. The molecular basis of canine pyruvate kinase deficiency. Exp Hematol 1994; 22:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/24\">",
"      Min-Oo G, Fortin A, Tam MF, et al. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet 2003; 35:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/25\">",
"      Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008; 358:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/26\">",
"      Pissard S, de Montalembert M, Bachir D, et al. Pyruvate kinase (PK) deficiency in newborns: the pitfalls of diagnosis. J Pediatr 2007; 150:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/27\">",
"      Ferreira P, Morais L, Costa R, et al. Hydrops fetalis associated with erythrocyte pyruvate kinase deficiency. Eur J Pediatr 2000; 159:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/28\">",
"      Amankwah KS, Dick BW, Dodge S. Hemolytic anemia and pyruvate kinase deficiency in pregnancy. Obstet Gynecol 1980; 55:42S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/29\">",
"      Mainwaring CJ, James CM, Butcher J, Clarke S. Haemolysis and the combined oral contraceptive pill? Br J Haematol 2001; 115:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/30\">",
"      Leblond PF, Lyonnais J, Delage JM. Erythrocyte populations in pyruvate kinase deficiency anaemia following splenectomy. I. Cell morphology. Br J Haematol 1978; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/31\">",
"      Leblond PF, Coulombe L, Lyonnais J. Erythrocyte populations in pyruvate kinase deficiency anaemia following splenectomy. II. Cell deformability. Br J Haematol 1978; 39:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/32\">",
"      Chandler FW Jr, Prasse KW, Callaway CS. Surface ultrastructure of pyruvate kinase-deficient erythrocytes in the Basenji dog. Am J Vet Res 1975; 36:1477.",
"     </a>",
"    </li>",
"    <li>",
"     Beutler E. Red cell metabolism: A manual of biochemical methods, Grune and Stratton, New York 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/34\">",
"      Lestas AN, Kay LA, Bellingham AJ. Red cell 3-phosphoglycerate level as a diagnostic aid in pyruvate kinase deficiency. Br J Haematol 1987; 67:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/35\">",
"      Beutler E. Editorial: Why has the autohemolysis test not gone the way of the cephalin flocculation test? Blood 1978; 51:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/36\">",
"      Miwa S, Nishina T, Kakehashi Y, et al. Studies on erythrocyte metabolism in a case with hereditary deficiency of H-subunit of lactate dehydrogenase. Nihon Ketsueki Gakkai Zasshi 1971; 34:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/37\">",
"      Baronciani L, Beutler E. Analysis of pyruvate kinase-deficiency mutations that produce nonspherocytic hemolytic anemia. Proc Natl Acad Sci U S A 1993; 90:4324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/38\">",
"      Baronciani L, Beutler E. Prenatal diagnosis of pyruvate kinase deficiency. Blood 1994; 84:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/39\">",
"      Tanphaichitr VS, Suvatte V, Issaragrisil S, et al. Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency. Bone Marrow Transplant 2000; 26:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/40\">",
"      Zanella A, Berzuini A, Colombo MB, et al. Iron status in red cell pyruvate kinase deficiency: study of Italian cases. Br J Haematol 1993; 83:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/41\">",
"      Zanella A, Bianchi P, Iurlo A, et al. Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases. Blood Cells Mol Dis 2001; 27:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/42\">",
"      Hilgard P, Gerken G. Liver cirrhosis as a consequence of iron overload caused by hereditary nonspherocytic hemolytic anemia. World J Gastroenterol 2005; 11:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/43\">",
"      Finkenstedt A, Bianchi P, Theurl I, et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br J Haematol 2009; 144:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/44\">",
"      Sandoval C, Stringel G, Weisberger J, Jayabose S. Failure of partial splenectomy to ameliorate the anemia of pyruvate kinase deficiency. J Pediatr Surg 1997; 32:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27559/abstract/45\">",
"      Tani K, Yoshikubo T, Ikebuchi K, et al. Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: implications for gene therapy of human PK deficiency. Blood 1994; 83:2305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7129 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27559=[""].join("\n");
var outline_f26_58_27559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13916755\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism for hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8012941\">",
"      Compensatory increase in oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6454714\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Folic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gene transfer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13916755\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7129|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/33/12830\" title=\"figure 1\">",
"      Glycolysis PK deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7129|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/9/31895\" title=\"picture 1\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7129|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/27/20924\" title=\"table 1\">",
"      Causes intra- and extra-vascular hemolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/45/10969?source=related_link\">",
"      Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27560="Lichen planus nail pterigium";
var content_f26_58_27560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Lichen planus of the nails permanent nail dystrophy leading to pterigium and anonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Permanent nail dystrophy resulting in anonychia and pterigium (extension and adherence of the proximal nail fold to the nail bed secondary to scarring of the nail matrix).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27560=[""].join("\n");
var outline_f26_58_27560=null;
var title_f26_58_27561="Treatment of echinococcosis";
var content_f26_58_27561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of echinococcosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Pedro L Moro, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27561/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/58/27561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinococcosis is caused by infection with the tapeworm echinococcus, which belongs to the family Taeniidae. Four species of echinococcus cause infection in humans. E. granulosus and E. multilocularis are the most common, causing cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. The two other species, E. vogeli and E. oligarthus, cause polycystic echinococcosis, but have been rarely associated with human infection. Two new species have been identified: Echinococcus shiquicus in small mammals from the Tibetan plateau and Echinococcus felidis in African lions; their transmission potential to humans is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of cystic and alveolar echinococcal infection will be reviewed here. The clinical manifestations, diagnosis, epidemiology, and control of echinococcal infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20407?source=see_link\">",
"     \"Epidemiology and control of echinococcosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CYSTIC ECHINOCOCCOSIS (E. GRANULOSUS)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5041303\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management options for cystic echinococcosis (CE) include surgery, percutaneous management, drug therapy, and observation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgery has been the traditional approach for treatment of CE; subsequently, alternative approaches have been introduced and have replaced surgery as the treatment of choice in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, clinical approach depends on the World Health Organization (WHO) diagnostic classification (",
"    <a class=\"graphic graphic_table graphicRef71806 \" href=\"UTD.htm?38/57/39836\">",
"     table 1",
"    </a>",
"    ). Stage CE1 and CE3a cysts have a single compartment; such cysts that are &lt;5 cm may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. In settings where albendazole treatment with follow-up monitoring is not feasible, definitive management with percutaneous treatment via PAIR (puncture, aspiration, injection, and reaspiration) is an acceptable alternative approach. Stage CE1 and CE3a cysts that are &gt;5 cm may be treated with albendazole in combination with PAIR. In situations where albendazole treatment is not feasible, percutaneous treatment with PAIR (in the absence of adjunctive drug therapy) is an acceptable alternative approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. Issues related to drug therapy are discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Drug therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Stage CE2 and CE3b cysts have many compartments that require individual puncture; patients with such cysts commonly relapse after PAIR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore management of these cysts requires either modified catheterization technique (eg, non-PAIR percutaneous therapy) or surgery (with adjunctive drug therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. The optimal choice between these approaches is uncertain and further study is needed.",
"   </p>",
"   <p>",
"    Stages CE4 and CE5 are inactive cysts that may be managed with observation.",
"   </p>",
"   <p>",
"    There are few randomized trials comparing different treatments, and the level of evidence supporting the use of one therapeutic modality over another is low. In one study of 32 patients with hepatic cysts comparing percutaneous drainage alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    alone, and percutaneous drainage in combination with albendazole, those who received combination therapy had the greatest size reduction observed ultrasonographically [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently, a randomized trial performed among 50 patients demonstrated that outcomes among those who underwent percutaneous drainage (in combination with albendazole) were comparable to outcomes among patients who underwent surgery (with no albendazole therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5041311\">",
"    <span class=\"h2\">",
"     Treatment modalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3785912\">",
"    <span class=\"h4\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for management of complicated cysts (eg, rupture cyst, cysts with biliary fistulae, cysts compressing vital structures, cysts with secondary infection or hemorrhage) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgery is also warranted for management of cysts with many daughter vesicles that are not suitable for percutaneous treatment (eg, WHO stage CE2 and CE3b) (",
"    <a class=\"graphic graphic_table graphicRef71806 \" href=\"UTD.htm?38/57/39836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Other indications for surgery include cyst diameter &gt;10 cm, superficial cyst at risk of rupture due to trauma, and extrahepatic disease (lung [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], bone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], brain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ], kidney, or other site) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/3,14-17\">",
"     3,14-17",
"    </a>",
"    ]. Surgery is also appropriate in settings where percutaneous treatment is not available.",
"   </p>",
"   <p>",
"    Adjunctive drug therapy should be administered to minimize risk of secondary echinococcosis from seeding of protoscolices in the abdominal cavity in the event of fluid spillage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is generally administered beginning one week prior to surgery and continued for at least four weeks postoperatively. Some use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    in addition to albendazole, although there is no clear evidence regarding its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3784862\">",
"     'Adjunctive treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery may cure the patient, but morbidity, mortality, and relapse rates can vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/13\">",
"     13",
"    </a>",
"    ]. Complications include secondary infection of cyst cavity, intraabdominal abscess, biliary fistula, sclerosing cholangitis, and spillage of cyst contents leading to secondary echinococcosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis. Postoperative complications occur in less than 1 percent of cases; recurrent echinococcosis occurs in 2 to 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. These rates depend on the location and size of the cyst and the surgeon&rsquo;s experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgical therapy consist of evacuating the cyst and obliterating the residual cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/16\">",
"     16",
"    </a>",
"    ]. Every effort should be made to avoid fluid spillage, which can lead to secondary seeding of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis. The safest and most effective surgical procedure is uncertain; the relative advantages of the different approaches have not been clearly established. Traditional approaches have included radical resection including pericystectomy, or more conservative techniques. Laparoscopic surgery may be an alternative to open surgery in some cases.",
"   </p>",
"   <p>",
"    The surgical approach must be individualized depending on the cyst features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/21\">",
"     21",
"    </a>",
"    ]. Removal of the intact cyst is preferred, if feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Alternatively, the cyst can be opened and sterilized with protoscolicidal agents, followed by evacuation of cyst contents and removal of the pericystic tissue. In one study including 132 patients with liver cysts treated with a variety of surgical procedures, cyst excision and omentoplasty were associated with the most favorable clinical results and lowest complication rates; a recurrence rate of 4.5 percent was observed with 4.5 years median follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Every effort should be made to avoid fluid spillage, which can lead to secondary seeding of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis. For circumstances in which intact removal of the cyst is not feasible, a protoscolicidal agent such as hypertonic saline should be injected into the cyst prior to removing the contents. In addition, the surgical field should be protected with pads soaked in protoscolicidal agents. However, protoscolicidal agents should not be used in the setting of biliary communication, to minimize the risk of sclerosing cholangitis or pancreatitis. The anatomy of biliary communication should be defined intraoperatively (radioopaque dye may be useful if available); any biliary leaks should be repaired surgically prior to application of the protoscolicidal agent.",
"   </p>",
"   <p>",
"    The most commonly used protoscolicidal agent is hypertonic saline (20 percent); the solution should be in contact with the germinal layer for at least 15 minutes (",
"    <a class=\"graphic graphic_figure graphicRef87460 \" href=\"UTD.htm?40/39/41589\">",
"     figure 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    solutions have been used as protoscolicidal agents, although their efficacy and safety require further study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Formalin has been associated with sclerosing cholangitis and should not be used.",
"   </p>",
"   <p>",
"    If spillage does occur, the peritoneum should be washed with hypertonic saline. The patient should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (three to six months) and a brief course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    (seven days) should also be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/29\">",
"     29",
"    </a>",
"    ]. The management of anaphylaxis is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic surgery has been described for treatment of echinococcus, although no randomized trials comparing laparoscopy with open procedures have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/3\">",
"     3",
"    </a>",
"    ]. Laparoscopy may be associated with increased risk of spillage due to elevated intraabdominal pressures caused by pneumoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/3\">",
"     3",
"    </a>",
"    ]. Laparoscopy is most likely to be successful in the setting of anteriorly located hepatic cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/30\">",
"     30",
"    </a>",
"    ]. Exclusion criteria for laparoscopy include deep intraparenchymal cysts, posterior cysts situated close to the vena cava, and presence of more than three cysts with calcified walls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/3,31-34\">",
"     3,31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical approaches for management of lung cysts include lobectomy, wedge resection, pericystectomy, intact endocystectomy, and capitonnage. In a study of 842 patients followed for 3 to 20 years, a recurrence rate of 1.9 percent was noted after intact endocystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2662872837\">",
"    <span class=\"h3\">",
"     Percutaneous management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two categories of percutaneous techniques. The first approach aims to destroy the germinal layer with scolicidal agents (",
"    <a class=\"graphic graphic_figure graphicRef87460 \" href=\"UTD.htm?40/39/41589\">",
"     figure 1",
"    </a>",
"    ). This is done via the PAIR (puncture, aspiration, injection of a scolicidal agent, and reaspiration) technique [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/36\">",
"     36",
"    </a>",
"    ]. PAIR is usually effective for definitive treatment of cysts that do not have daughter cysts (eg, WHO stage CE1 and CE3a).",
"   </p>",
"   <p>",
"    The second approach consists of evacuating the entire cyst with a large bore catheter. This is generally done for management of cysts that are difficult to drain or tend to relapse after PAIR, such as WHO stage CE2 and CE3b cysts (which may contain daughter cysts). Establishing whether daughter cysts are present is important for guiding treatment, since the presence of daughter cysts reduces the likelihood of successful definitive treatment with PAIR.",
"   </p>",
"   <p>",
"    Percutaneous treatment is associated with risk for anaphylaxis; in one review of treatment for nearly 6000 cysts, anaphylaxis occurred in 1.6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    should be administered for at least one month following percutaneous treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3784862\">",
"     'Adjunctive treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     PAIR procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAIR is less invasive than surgery and can be both a diagnostic and therapeutic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/38\">",
"     38",
"    </a>",
"    ]. The cure rate with PAIR for appropriately selected cysts is &gt;95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Among 231 liver cysts in 163 Italian patients treated with PAIR (ethanol was the scolicidal agent), one relapse was observed after four years of follow-up; this was successfully treated with repeat PAIR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/40\">",
"     40",
"    </a>",
"    ]. Establishing whether daughter cysts are present is important for guiding treatment, since the presence of daughter cysts generally precludes use of PAIR for definitive management.",
"   </p>",
"   <p>",
"    PAIR may be used for primary treatment of WHO stage CE1 and CE3a cysts (eg cysts that do not have daughter cysts), for treatment following relapse of CE1 or CE3a cysts managed previously with medical therapy alone, or for treatment following relapse after surgery (in the absence of daughter cysts). PAIR has been used successfully for management of cysts in the liver and other abdominal sites (eg, abdominal cavity, spleen, kidney), although many experts would approach these lesions surgically. Cysts in extraabdominal sites such as lung or bone are less amenable to management with PAIR.",
"   </p>",
"   <p>",
"    PAIR is performed under ultrasound or computed tomography (CT) guidance. Following cyst puncture, aspirated fluid should be evaluated histopathologically for presence of protoscolices. Following injection of the protoscolicidal agent, reaspiration should be performed after at least 10 to 15 minutes. The presence of protoscolices in the reaspirated fluid should prompt repeat protoscolicidal injection. Follow-up after PAIR is discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adjunctive drug therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    should be administered at least four hours prior to PAIR. Albendazole should be continued for one month after the procedure; mebendazole should be continued for three months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1,14,20\">",
"     1,14,20",
"    </a>",
"    ]. Issues related to drug therapy are discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Drug therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Further study is needed regarding the optimal approach, including use of needle versus catheter, quantity of protoscolicidal agent, and duration of follow-up required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PAIR should not be performed in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cyst with nondrainable solid material or echogenic foci",
"     </li>",
"     <li>",
"      Superficial cyst at risk of rupture into the abdominal cavity",
"     </li>",
"     <li>",
"      Cyst that has ruptured into the peritoneum",
"     </li>",
"     <li>",
"      Cyst with biliary communication",
"     </li>",
"     <li>",
"      Inactive or calcified cyst",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risks of PAIR include spillage of cyst contents into the peritoneum (which can lead to secondary echinococcosis, urticaria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis), chemical sclerosing cholangitis, biliary fistula (6 percent), local recurrence (3 percent), and bleeding and infection (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/41,43-45\">",
"     41,43-45",
"    </a>",
"    ]. Fever and urticaria occur in 11 to 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]; the risk of anaphylaxis is 0.5 percent and has been reduced with development of fine needles and catheters and advances in imaging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopy can be useful both before and after PAIR to evaluate for cyst communication with the biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/40,46\">",
"     40,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=see_link&amp;anchor=H6#H6\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\", section on 'Echinococcus granulosus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2662872905\">",
"    <span class=\"h4\">",
"     Modified catheterization techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modified catheterization techniques are used to remove the entire endocyst and daughter cysts from the cyst cavity using large-bore catheters and cutting devices together with an aspiration apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. This approach (in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    if available) may be appropriate for cysts that are difficult to drain via PAIR, and for management of WHO stage CE2 and CE3b cysts, which have many compartments so commonly relapse after PAIR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/4\">",
"     4",
"    </a>",
"    ]. The alternative management for such cysts is surgery. The optimal choice between these approaches is uncertain. Experience with modified catheterization techniques and data regarding outcomes are limited; further study is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy may be used for definitive management in selected cases; it is also a useful adjunctive therapy to surgery and percutaneous treatment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is the primary antiparasitic agent for treatment of E. granulosus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ]. Albendazole is poorly absorbed and should be ingested with food, ideally with a fatty meal to increase bioavailability (15",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    divided into two doses, to maximum 400 mg orally twice daily with food). In the absence of albendazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    may be used as an alternative therapy; it is less well absorbed than albendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10362016\">",
"    <span class=\"h4\">",
"     Definitive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management with drug treatment alone is appropriate for management of small WHO stage CE1 and CE3a cysts (eg cysts with a single compartment and diameter &lt;5 cm). Treatment should be administered without interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. The optimal duration is uncertain; one to three months may be appropriate, depending clinical factors; up to six months may be required.",
"   </p>",
"   <p>",
"    Drug treatment alone is usually not effective for treatment of cysts with diameter &gt;5 cm, or for treatment of WHO stage CE2 or CE3b cysts (which have multiple compartments) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/47\">",
"     47",
"    </a>",
"    ]. Other circumstances in which drug treatment alone may be warranted include management of multiple liver cysts &lt;5 cm, management of cysts deep in liver parenchyma that are not amenable to percutaneous treatment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritoneal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3784862\">",
"    <span class=\"h4\">",
"     Adjunctive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug treatment is a useful adjunctive therapy to surgery and percutaneous treatment. Perioperative drug therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    ) reduces the risk of recurrent disease by inactivating protoscolices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. It also softens the cyst, facilitating removal. The optimal duration of treatment is uncertain; in general treatment should be initiated at least 4 days prior to surgery (the WHO suggests 4 to 30 days preoperatively) and should be continued for at least 1 month (albendazole) or 3 months (mebendazole) following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug treatment may be appropriate for patients who cannot undergo definitive cyst removal via percutaneous treatment or surgery, although drug treatment alone is generally not sufficient for definitive management in such cases. Drug treatment is also appropriate following spontaneous cyst rupture to reduce the risk of secondary echinococcosis from seeding of protoscolices in the abdominal cavity for one month (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    ) or three months (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16943617\">",
"    <span class=\"h4\">",
"     Drug selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is the primary antiparasitic agent for treatment of E. granulosus; availability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cost may be prohibitive in some regions.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    are less effective agents; in the absence of albendazole, mebendazole may be used as an alternative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    inhibits microtubules assembly, leading to impaired glucose absorption and causing glycogen depletion followed by degeneration of the endoplasmic reticulum and mitochondria of the germinal layer, leading to cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/54\">",
"     54",
"    </a>",
"    ]. The outcome of treatment with albendazole depends on host characteristics, cyst size, age, and location [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/55\">",
"     55",
"    </a>",
"    ]. Cumulative experience with albendazole suggests that treatment leads to cyst resolution in up to 30 percent of patients, size reduction in another 30 to 50 percent, and no change in 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. A lower likelihood of response has been observed in the setting of older patient age and longer duration of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    has a more favorable pharmacokinetic profile than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    , and may be given for a shorter duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/10,47,56,59-68\">",
"     10,47,56,59-68",
"    </a>",
"    ]. Albendazole is usually dosed 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses; the usual dose for adults is 400 mg twice daily. Absorption is improved by taking albendazole with a fatty meal. Mebendazole is dosed 40 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is generally well tolerated. Adverse effects include reversible hepatotoxicity (1 to 5 percent), cytopenia (&lt;1 percent), and alopecia (&lt;1 percent). Increased levels of aminotransferases may occur as a result of drug toxicity or parasite killing. Rarely, agranulocytosis has been reported. Dizziness, headache, vomiting, and rash have also been described. These drugs should not be used in patients with significant underlying liver disease or bone marrow suppression. Laboratory monitoring including blood count and liver function tests should be checked at two-week intervals for the first three months, then monthly.",
"   </p>",
"   <p>",
"    An increase in aminotransferases that is more than fivefold above the upper limit of normal should prompt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    and consideration of alternative treatment approaches such as percutaneous or surgical management. If an alternative therapeutic agent is required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    may be a reasonable alternative to albendazole.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    should be avoided during pregnancy because of potential teratogenicity; if feasible, treatment should be delayed until after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"     1",
"    </a>",
"    ]. Data on use of albendazole in children &lt;6 years are limited.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    has been shown to have protoscolicidal activity, although the efficacy of praziquantel in clinical studies is variable, and thus far it does not have a definitive role for primary drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/19,69-71\">",
"     19,69-71",
"    </a>",
"    ]. Praziquantel has been used alone and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/19,29,55,69,72-74\">",
"     19,29,55,69,72-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24209108\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that, in the absence of complications, inactive liver cysts (eg, WHO stage CE4 and CE5) can be monitored in the absence of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/4,17,75\">",
"     4,17,75",
"    </a>",
"    ]. Prospective studies evaluating this approach are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic echinococcus (CE) can relapse years after treatment. Evaluating the success of therapy can is difficult since the natural history of infection can be highly variable. Cysts may continue growing (1 to 50 mm per year), persist with no change, rupture spontaneously, or resolve completely.",
"   </p>",
"   <p>",
"    The optimal approach to monitoring is uncertain and must be individualized according to patient characteristics and available resources [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/76\">",
"     76",
"    </a>",
"    ]. Follow-up usually consists of ultrasound or other imaging (CT or MRI) at three- to six-month intervals until the findings are stable, followed by yearly monitoring. Follow-up for up to 5 years is usually warranted to evaluate for recurrence; in some cases, 3 years may be sufficient if radiographic findings are stable at 12, 24, and 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13253170\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography may be useful in assessing the response to therapy, but has limitations. Ultrasound findings that appear to correlate with effective therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/5,77\">",
"     5,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete cyst disappearance",
"     </li>",
"     <li>",
"      Reduction in cyst size and volume",
"     </li>",
"     <li>",
"      Increase in proportion of solid component of cyst",
"     </li>",
"     <li>",
"      Thickening and irregularity of the cyst wall",
"     </li>",
"     <li>",
"      Within multivesicular cysts, reduction in size",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      number of daughter cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasound findings that appear to correlate with relapse include development of new cysts, increase in cyst size or volume, and increase in liquid component of the cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound lacks sensitivity for determination of cyst viability; in one study including 55 patients, no ultrasonographic changes were observed among 41 percent of nonviable cysts surgically removed following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On CT or MRI, degenerating cysts are often surrounded by a dense halo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal serologic test for monitoring patients on treatment for hydatid disease is uncertain. Frequently, serologic titers fall one to two years following successful surgery, and rise again in the setting of recurrence. However, antibodies may remain elevated even many years after successful cyst removal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/55,79\">",
"     55,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some antigens that appear promising for use of serology in monitoring following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. One study evaluated six serologic tests for postoperative monitoring of pulmonary hydatid disease in 79 surgically-confirmed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/82\">",
"     82",
"    </a>",
"    ]. Latex agglutination, passive hemagglutination, immunoelectrophoresis, and specific IgE, IgM, and IgG ELISA tests were used. All tests showed an increase in titer in the majority of patients within the first three months after surgery, likely as a result of antigen release during cyst manipulation. Specific IgG ELISA was the most sensitive measure of response to treatment (84 percent); specific IgE ELISA was the least sensitive (44 percent). All serologic tests showed decreasing antibody titers from three months after surgery in patients without relapse; immunoelectrophoresis, specific IgE ELISA, and specific IgM ELISA tests became negative at two years. Specific IgG ELISA was the slowest to become negative and was still positive five years after surgery in 17 percent of cases. Patients who relapsed showed either persistently high (early relapse) or initial decrease and subsequent increase (late relapse) in antibody titers in all serologic tests.",
"   </p>",
"   <p>",
"    Other studies have suggested that less sensitive tests such as immunoelectrophoresis and",
"    <span class=\"nowrap\">",
"     IgM/IgE",
"    </span>",
"    ELISA become negative earlier after successful treatment than more sensitive tests such as hemagglutination, latex agglutination or specific IgG ELISA. The more sensitive tests may be positive in &gt;40 percent of patients 4 to 5 years after surgery, and can remain positive for more than 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ALVEOLAR ECHINOCOCCOSIS (E. MULTILOCULARIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of alveolar echinococcosis (AE) due to E. multilocularis is generally less effective than the treatment for cystic echinococcus (CE) due to E. granulosus.",
"   </p>",
"   <p>",
"    In general, the approach to treatment of AE consists of surgery. Infected tissues should be removed as completely as possible, which requires complete excision of parasitic tissue and may also warrant radical resection of host tissue. The feasibility of radical resection depends on the site of the lesion, presence of metastases, patient comorbidities, and available surgical expertise.",
"   </p>",
"   <p>",
"    The benefit of routine preoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    administration is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ]. Postoperatively, albendazole (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses; usual adult dose 400 mg twice daily) should be administered to reduce the likelihood of relapse, even in cases of apparent cure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/7\">",
"     7",
"    </a>",
"    ]. Alternative agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    and amphotericin are less effective than albendazole [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is uncertain; in general, at least 2 years of therapy is advisable in conjunction with at least 10 years of follow-up monitoring for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/57\">",
"     57",
"    </a>",
"    ]. Local complications may develop that warrant intervention such as stenting, drainage of necrotic liver lesions, or endoscopic sclerosing of esophageal varices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of palliative surgery is limited; in some cases, it may reduce the burden of infection and increase the benefit of adjunctive drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases that are not amenable to definitive surgery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    should be administered indefinitely to suppress progression of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/86\">",
"     86",
"    </a>",
"    ]. In such cases, albendazole is not curative, but can improve quality of life and prolong survival. Survival rates at 15 years of 53 to 80 percent have been observed with palliative albendazole in the absence of surgery (versus 15 year mortality rate of 100 percent without treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/87-93\">",
"     87-93",
"    </a>",
"    ]. Approximately half of patients respond with regression or lesion stabilization.",
"   </p>",
"   <p>",
"    As a last resort, liver transplantation may be a consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27561/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3785987\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management options for cystic echinococcosis (CE) include surgery, percutaneous management, drug therapy, and observation. In general, clinical approach depends on the World Health Organization (WHO) diagnostic classification (",
"      <a class=\"graphic graphic_table graphicRef71806 \" href=\"UTD.htm?38/57/39836\">",
"       table 1",
"      </a>",
"      ). There are few randomized trials comparing different treatments, and the level of evidence supporting the use of one therapeutic modality over another is low. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cystic echinococcosis (E. granulosus)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WHO stage CE1 and CE3a cysts have a single compartment; such cysts &lt;5 cm may be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      alone. In settings where albendazole treatment with follow-up monitoring is not feasible, definitive management with percutaneous treatment via PAIR (puncture, aspiration, injection, and reaspiration) is an acceptable alternative approach. (See",
"      <a class=\"local\" href=\"#H5041303\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WHO stage CE1 and CE3a cysts that are &gt;5 cm may be treated with PAIR and adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      . In situations where albendazole treatment is not feasible, percutaneous treatment with PAIR (in the absence of adjunctive drug therapy) is an acceptable alternative approach. (See",
"      <a class=\"local\" href=\"#H5041303\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      WHO stage CE2 and CE3b cysts have many compartments that require individual puncture; patients with such cysts commonly relapse after PAIR. Therefore, management of these cysts requires either modified catheterization technique (eg, non-PAIR percutaneous therapy) or surgery, with adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5041303\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every effort should be made to avoid spillage of cyst contents, which can lead to secondary seeding of infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anaphylaxis. For circumstances in which intact removal of the cyst is not feasible, a protoscolicidal agent should be injected into the cyst prior to removing the contents. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      for drug treatment of E. granulosus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); in the absence of albendazole,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      may be used as an alternative therapy. Albendazole is dosed 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two divided doses; the usual dose for adults is 400 mg twice daily, taken with food. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of definitive and adjunctive drug therapy is uncertain. Drug therapy for definitive treatment generally consists of one to three months; up to six months may be required. Drug therapy for adjunctive therapy consists of 4 to 30 days preoperatively and at least 4 weeks postoperatively.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       Albendazole",
"      </a>",
"      should be administered continuously, without interruption. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CE can relapse years after treatment. The optimal approach to monitoring is uncertain and must be individualized. Follow-up for up to 5 years is warranted to evaluate for recurrence; 3 years may be sufficient if there is no recurrence on imaging studies at 12, 24, and 36 months. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the approach to treatment of alveolar echinococcus (AE) consists of surgery. Infected tissues should be removed as completely as possible, which requires complete excision of parasitic tissue and may also warrant radical resection of host tissue. In general, at least 2 years of adjunctive drug therapy is advisable in conjunction with at least 10 years of follow-up monitoring for recurrence. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Alveolar echinococcosis (E. multilocularis)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110953210\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/1\">",
"      Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/2\">",
"      Menezes da Silva A. Hydatid cyst of the liver-criteria for the selection of appropriate treatment. Acta Trop 2003; 85:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/3\">",
"      Dervenis C, Delis S, Avgerinos C, et al. Changing concepts in the management of liver hydatid disease. J Gastrointest Surg 2005; 9:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/4\">",
"      Brunetti E, Garcia HH, Junghanss T, International CE Workshop in Lima, Peru, 2009. Cystic echinococcosis: chronic, complex, and still neglected. PLoS Negl Trop Dis 2011; 5:e1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/5\">",
"      Khuroo MS, Dar MY, Yattoo GN, et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 1993; 104:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/6\">",
"      Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997; 337:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/7\">",
"      Brunetti E, White AC Jr. Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am 2012; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/8\">",
"      Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/9\">",
"      Keshmiri M, Baharvahdat H, Fattahi SH, et al. A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis. Eur Respir J 1999; 14:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/10\">",
"      Todorov T, Mechkov G, Vutova K, et al. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ 1992; 70:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/11\">",
"      Zlitni M, Ezzaouia K, Lebib H, et al. Hydatid cyst of bone: diagnosis and treatment. World J Surg 2001; 25:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/12\">",
"      Singounas EG, Leventis AS, Sakas DE, et al. Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature. Neurosurgery 1992; 31:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/13\">",
"      Todorov T, Vutova K, Petkov D, Balkanski G. Albendazole treatment of multiple cerebral hydatid cysts: case report. Trans R Soc Trop Med Hyg 1988; 82:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/14\">",
"      Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ 1996; 74:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/15\">",
"      Anadol D, Oz&ccedil;elik U, Kiper N, G&ouml;&ccedil;men A. Treatment of hydatid disease. Paediatr Drugs 2001; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/16\">",
"      Safioleas MC, Misiakos EP, Kouvaraki M, et al. Hydatid disease of the liver: a continuing surgical problem. Arch Surg 2006; 141:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/17\">",
"      Junghanss T, da Silva AM, Horton J, et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 2008; 79:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/18\">",
"      Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop 2009; 111:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/19\">",
"      Cobo F, Yarnoz C, Sesma B, et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health 1998; 3:462.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO) Informal Working Group of Echinococcosis. Puncture, Aspiration, Injection, Re-Aspiration. An option for the treatment of cystic echinococcosis, p. 1&ndash;40. Document WHO/CDS/CSR/SPH/2001.6. Geneva, Switzerland: WHO; 2001. pp. 1&ndash;40.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/21\">",
"      Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis 2009; 13:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/22\">",
"      Magistrelli P, Masetti R, Coppola R, et al. Surgical treatment of hydatid disease of the liver. A 20-year experience. Arch Surg 1991; 126:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/23\">",
"      Behrns KE, van Heerden JA. Surgical management of hepatic hydatid disease. Mayo Clin Proc 1991; 66:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/24\">",
"      Di Matteo G, Bove A, Chiarini S, et al. Hepatic echinococcus disease: our experience over 22 years. Hepatogastroenterology 1996; 43:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/25\">",
"      Balik AA, Ba��o��lu M, Celebi F, et al. Surgical treatment of hydatid disease of the liver: review of 304 cases. Arch Surg 1999; 134:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/26\">",
"      Safioleas M, Misiakos E, Manti C, et al. Diagnostic evaluation and surgical management of hydatid disease of the liver. World J Surg 1994; 18:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/27\">",
"      Paksoy Y, Odev K, Sahin M, et al. Percutaneous treatment of liver hydatid cysts: comparison of direct injection of albendazole and hypertonic saline solution. AJR Am J Roentgenol 2005; 185:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/28\">",
"      Dziri C, Haouet K, Fingerhut A, Zaouche A. Management of cystic echinococcosis complications and dissemination: where is the evidence? World J Surg 2009; 33:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/29\">",
"      Taylor DH, Morris DL. Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone. Br J Surg 1989; 76:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/30\">",
"      Bickel A, Daud G, Urbach D, et al. Laparoscopic approach to hydatid liver cysts. Is it logical? Physical, experimental, and practical aspects. Surg Endosc 1998; 12:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/31\">",
"      Baskaran V, Patnaik PK. Feasibility and safety of laparoscopic management of hydatid disease of the liver. JSLS 2004; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/32\">",
"      Chowbey PK, Shah S, Khullar R, et al. Minimal access surgery for hydatid cyst disease: laparoscopic, thoracoscopic, and retroperitoneoscopic approach. J Laparoendosc Adv Surg Tech A 2003; 13:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/33\">",
"      Ertem M, Karahasanoglu T, Yavuz N, Erguney S. Laparoscopically treated liver hydatid cysts. Arch Surg 2002; 137:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/34\">",
"      Seven R, Berber E, Mercan S, et al. Laparoscopic treatment of hepatic hydatid cysts. Surgery 2000; 128:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/35\">",
"      Qian ZX. Thoracic hydatid cysts: a report of 842 cases treated over a thirty-year period. Ann Thorac Surg 1988; 46:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/36\">",
"      Nasseri Moghaddam S, Abrishami A, Malekzadeh R. Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev 2006; :CD003623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/37\">",
"      Neumayr A, Troia G, de Bernardis C, et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review. PLoS Negl Trop Dis 2011; 5:e1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/38\">",
"      Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003; 37:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/39\">",
"      Salama H, Farid Abdel-Wahab M, Strickland GT. Diagnosis and treatment of hepatic hydatid cysts with the aid of echo-guided percutaneous cyst puncture. Clin Infect Dis 1995; 21:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/40\">",
"      Filice C, Brunetti E. Use of PAIR in human cystic echinococcosis. Acta Trop 1997; 64:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/41\">",
"      Ust&uuml;ns&ouml;z B, Akhan O, Kamilo��lu MA, et al. Percutaneous treatment of hydatid cysts of the liver: long-term results. AJR Am J Roentgenol 1999; 172:91.",
"     </a>",
"    </li>",
"    <li>",
"     www.medicalweb.it/aumi/echinonet/ (Accessed on December 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/43\">",
"      Men S, Hekimo��lu B, Y&uuml;cesoy C, et al. Percutaneous treatment of hepatic hydatid cysts: an alternative to surgery. AJR Am J Roentgenol 1999; 172:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/44\">",
"      Akhan O, Ozmen MN, Din&ccedil;er A, et al. Liver hydatid disease: long-term results of percutaneous treatment. Radiology 1996; 198:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/45\">",
"      Yagci G, Ustunsoz B, Kaymakcioglu N, et al. Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients. World J Surg 2005; 29:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/46\">",
"      Filice C, Brunetti E. Echo-guided diagnosis and treatment of hepatic hydatid cysts. Clin Infect Dis 1997; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/47\">",
"      Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 2009; 3:e524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/48\">",
"      Aktan AO, Yalin R. Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Eur J Gastroenterol Hepatol 1996; 8:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/49\">",
"      Erzurumlu K, H&ouml;kelek M, G&ouml;nl&uuml;sen L, et al. The effect of albendazole on the prevention of secondary hydatidosis. Hepatogastroenterology 2000; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/50\">",
"      Arif SH, Wani NA, Zargar SA, et al. Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver. Int J Surg 2008; 6:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/51\">",
"      Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 1993; 342:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/52\">",
"      Bildik N, Cevik A, Altinta�� M, et al. Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol 2007; 41:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/53\">",
"      Manterola C, Mansilla JA, Fonseca F. Preoperative albendazole and scolices viability in patients with hepatic echinococcosis. World J Surg 2005; 29:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/54\">",
"      Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 1982; 67:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/55\">",
"      El-On J. Benzimidazole treatment of cystic echinococcosis. Acta Trop 2003; 85:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/56\">",
"      Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997; 64:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/57\">",
"      Ammann RW, Eckert J. Cestodes. Echinococcus. Gastroenterol Clin North Am 1996; 25:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/58\">",
"      Bezzi M, Teggi A, De Rosa F, et al. Abdominal hydatid disease: US findings during medical treatment. Radiology 1987; 162:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/59\">",
"      Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 1989; 67:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/60\">",
"      Todorov T, Vutova K, Mechkov G, et al. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol 1992; 86:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/61\">",
"      Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 1993; 37:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/62\">",
"      Todorov T, Vutova K, Mechkov G, et al. Evaluation of response to chemotherapy of human cystic echinococcosis. Br J Radiol 1990; 63:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/63\">",
"      Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg 1989; 83:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/64\">",
"      Vutova K, Mechkov G, Vachkov P, et al. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999; 93:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/65\">",
"      Todorov T, Vutova K, Petkov D, et al. Albendazole treatment of human cystic echinococcosis. Trans R Soc Trop Med Hyg 1988; 82:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/66\">",
"      Franchi C, Di Vico B, Teggi A. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. Clin Infect Dis 1999; 29:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/67\">",
"      Keshmiri M, Baharvahdat H, Fattahi SH, et al. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg 2001; 95:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/68\">",
"      Morris DL, Dykes PW, Marriner S, et al. Albendazole--objective evidence of response in human hydatid disease. JAMA 1985; 253:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/69\">",
"      Mohamed AE, Yasawy MI, Al Karawi MA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998; 45:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/70\">",
"      Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 1993; 35:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/71\">",
"      Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005; 9:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/72\">",
"      McManus DP, Zhang W, Li J, Bartley PB. Echinococcosis. Lancet 2003; 362:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/73\">",
"      Yasawy MI, al Karawi MA, Mohamed AR. Combination of praziquantel and albendazole in the treatment of hydatid disease. Trop Med Parasitol 1993; 44:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/74\">",
"      Yasawy MI, Alkarawi MA, Mohammed AR. Prospects in medical management of Echinococcus granulosus. Hepatogastroenterology 2001; 48:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/75\">",
"      Brunetti E, Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis 2009; 22:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/76\">",
"      Golemanov B, Grigorov N, Mitova R, et al. Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria. Am J Trop Med Hyg 2011; 84:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/77\">",
"      Sciarrino E, Virdone R, Lo Iacono O, et al. Ultrasound changes in abdominal echinococcosis treated with albendazole. J Clin Ultrasound 1991; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Echinonet. Online version of Echinonews. 2000. Available at: www.medicalweb.it/aumi/echinonet/ (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/79\">",
"      Galitza Z, Bazarsky E, Sneier R, et al. Repeated treatment of cystic echinococcosis in patients with a long-term immunological response after successful surgical cyst removal. Trans R Soc Trop Med Hyg 2006; 100:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/80\">",
"      Ben Nouir N, Nu&ntilde;ez S, Gianinazzi C, et al. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis. J Clin Microbiol 2008; 46:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/81\">",
"      Ben Nouir N, Gianinazzi C, Gorcii M, et al. Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients. Trans R Soc Trop Med Hyg 2009; 103:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/82\">",
"      Zarzosa MP, Ordu&ntilde;a Domingo A, Guti&eacute;rrez P, et al. Evaluation of six serological tests in diagnosis and postoperative control of pulmonary hydatid disease patients. Diagn Microbiol Infect Dis 1999; 35:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/83\">",
"      Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/84\">",
"      Reuter S, Buck A, Grebe O, et al. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob Agents Chemother 2003; 47:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/85\">",
"      Kadry Z, Renner EC, Bachmann LM, et al. Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 2005; 92:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/86\">",
"      Torgerson PR, Schweiger A, Deplazes P, et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol 2008; 49:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/87\">",
"      Ammann RW, Hirsbrunner R, Cotting J, et al. Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990; 43:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/88\">",
"      Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992; 15:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/89\">",
"      Wilson JF, Rausch RL, Wilson FR. Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg 1995; 221:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/90\">",
"      Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998; 29:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/91\">",
"      Wilson JF, Rausch RL, McMahon BJ, et al. Albendazole therapy in alveolar hydatid disease: a report of favorable results in two patients after short-term therapy. Am J Trop Med Hyg 1987; 37:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/92\">",
"      Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994; 19:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/93\">",
"      Ishizu H, Uchino J, Sato N, et al. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 1997; 25:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/94\">",
"      Bresson-Hadni S, Koch S, Beurton I, et al. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 1999; 30:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27561/abstract/95\">",
"      Bresson-Hadni S, Blagosklonov O, Knapp J, et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl 2011; 17:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5671 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-024AF9ABBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27561=[""].join("\n");
var outline_f26_58_27561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3785987\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CYSTIC ECHINOCOCCOSIS (E. GRANULOSUS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5041303\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5041311\">",
"      Treatment modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3785912\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2662872837\">",
"      - Percutaneous management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PAIR procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2662872905\">",
"      Modified catheterization techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10362016\">",
"      Definitive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3784862\">",
"      Adjunctive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16943617\">",
"      Drug selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24209108\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13253170\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ALVEOLAR ECHINOCOCCOSIS (E. MULTILOCULARIS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3785987\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110953210\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5671|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/39/41589\" title=\"figure 1\">",
"      Structure of the echinococcal cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/57/39836\" title=\"table 1\">",
"      Cystic echinococcus classification and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20407?source=related_link\">",
"      Epidemiology and control of echinococcosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27562="Evaluation of the adult with acute weakness in the emergency department";
var content_f26_58_27562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the adult with acute weakness in the emergency department",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Andrew W Asimos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/58/27562/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/58/27562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness is a common, nonspecific emergency department (ED) complaint that encompasses a broad differential diagnosis. Causes include neurologic ailments and a range of non-neurologic conditions. The diagnosis of potentially life-threatening neurologic and neuromuscular processes requires a systematic, anatomic approach based upon a careful history, physical examination, and in some cases, imaging studies.",
"   </p>",
"   <p>",
"    Particularly in the elderly, infection, cardiovascular disease, and dehydration must be considered as possible causes of weakness. However, such conditions cause generalized malaise rather than true neuromuscular weakness and will not be discussed here, except to mention them as important considerations in the differential diagnosis.",
"   </p>",
"   <p>",
"    The approach to the diagnosis and initial management of patients presenting to the ED with acute, nontraumatic neurologic and neuromuscular weakness will be reviewed here. Medical conditions characterized by general malaise or chronic weakness is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF ACUTE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this topic reviews the approach to the patient with acute weakness from nontraumatic neurologic or neuromuscular disease, a broad differential diagnosis, including causes of generalized weakness (or malaise), is presented here to assist clinicians looking for additional information about these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening central causes of unilateral weakness",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic stroke &ndash; Sudden loss of focal brain function is the core feature of the onset of ischemic stroke. This may manifest as acute, focal, unilateral weakness or paralysis in the face, upper extremity, or lower extremity, or as difficulty with coordination and gait. Other medical illness can mimic stroke (",
"      <a class=\"graphic graphic_table graphicRef69869 \" href=\"UTD.htm?26/51/27451\">",
"       table 1",
"      </a>",
"      ), and symptoms of stroke can vary widely based upon the cause and the artery involved (",
"      <a class=\"graphic graphic_table graphicRef69907 \" href=\"UTD.htm?42/25/43419\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75487 \" href=\"UTD.htm?27/15/27900\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"       \"Initial assessment and management of acute stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage &ndash; The neurologic symptoms and signs associated with intracerebral hemorrhage frequently worsen over minutes to hours, in contrast to ischemic stroke and subarachnoid hemorrhage. Headache, vomiting, seizures, and a decreased level of consciousness often occur. Unilateral weakness or paralysis may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"       \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage (SAH) &ndash; Sudden onset of severe headache is the most common presentation of SAH. This may be accompanied by loss of consciousness, seizure, nausea and vomiting, and meningismus. Lateralizing signs, such as unilateral weakness, are uncommon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life-threatening and other serious causes of bilateral weakness",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Brainstem stroke",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brainstem stroke &ndash; Lesions in the brainstem may produce ipsilateral cranial nerve and contralateral body weakness. Clinical findings vary depending upon the areas involved but may include dizziness, depressed mental status, visual field deficits, oculomotor abnormalities, bulbar findings, and respiratory dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"       \"Posterior circulation cerebrovascular syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Spinal cord disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinal cord inflammation or compression &ndash; A spinal cord lesion may be suspected when there are bilateral motor and sensory signs or symptoms that do not involve the head. Motor deficits involve weakness, muscle spasticity, and hyperreflexia (although hyporeflexia is often seen acutely); sensory findings involve a discrete level below which sensation is absent or reduced. A wide range of pathologies can cause spinal cord disease, including trauma, infection (eg, epidural abscess), neoplasm, hemorrhage, inflammation (eg, transverse myelitis), and degenerative disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"       \"Disorders affecting the spinal cord\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"       \"Anatomy and localization of spinal cord disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Peripheral nerve disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guillain-Barr&eacute; syndrome (GBS) &ndash; Patients with GBS frequently present to the ED with a complaint of numbness or paresthesias in the limbs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. The cardinal clinical features of GBS consist of progressive, fairly symmetric muscle weakness accompanied by absent or depressed deep tendon reflexes. Patients usually present a few days to a week after onset. Weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremity, facial, respiratory, and bulbar muscles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tick paralysis &ndash; Tick paralysis caused by Dermacentor ticks usually begins with paresthesias and a sense of fatigue and weakness. Fever is characteristically absent. Despite patients' reports of paresthesias, the sensory exam is typically normal. Most patients eventually develop an unsteady gait that progresses to an ascending complete paralysis. Deep tendon reflexes are characteristically absent. Respiratory paralysis and death can occur in severe cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=see_link\">",
"       \"Tick paralysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neuromuscular junction disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenia gravis (MG) &ndash; MG can produce weakness in any muscle group. Certain presentations are more common: ocular symptoms (eg, ptosis, diplopia) occur in 50 percent; bulbar symptoms (eg, dysarthria, dysphagia, fatigable chewing) occur in about 15 percent; and isolated limb weakness occurs in about 5 percent. Myasthenic crisis occurs when respiratory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bulbar muscle weakness produces acute respiratory distress. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Organophosphate and carbamate poisoning &ndash; Acute toxicity from organophosphorus agents presents with manifestations of cholinergic excess. The dominant clinical features include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, diarrhea, diaphoresis, and generalized weakness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"       \"Organophosphate and carbamate poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Botulism &ndash; Patients with food-borne botulism may have a prodrome of vomiting, abdominal pain, diarrhea, and dry mouth. Symptoms of cranial nerve involvement then develop (eg, fixed pupillary dilation, diplopia, nystagmus, ptosis, dysphagia, dysarthria), followed by descending muscle weakness, which usually progresses from the trunk and upper extremities to the lower extremities. Smooth muscle paralysis leads to urinary retention; diaphragmatic paralysis can lead to respiratory distress requiring intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"       \"Botulism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Muscle disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic myopathy &ndash; This myopathy occurs in long-standing alcoholics, presents with muscle cramps, tenderness, and swelling, and is a major cause of nontraumatic rhabdomyolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link&amp;anchor=H4#H4\">",
"       \"Drug-induced myopathies\", section on 'Alcohol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myositis &ndash; Both dermatomyositis and polymyositis usually present with symmetric proximal muscle weakness, which has often been worsening over several months. Muscle pain and tenderness is present in up to half of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Life-threatening medical causes with focal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic conditions most often cause generalized weakness without focal findings. However, exceptions exist, most notably hypoglycemia and hypokalemic periodic paralysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia &ndash; Symptoms and signs of severe hypoglycemia are nonspecific and can include fatigue, dizziness, visual disturbances, drowsiness, dysarthria, and depressed mental status. Untreated, symptoms can progress to seizures or coma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"       \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic paralysis &ndash; Severe electrolyte abnormalities can cause generalized or focal muscle weakness. Hypo- or hyperkalemia, hypo- or hypercalcemia, hypomagnesemia, or hypophosphatemia may be the cause, and are discussed separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Potassium disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14137?source=see_link&amp;anchor=H13#H13\">",
"       \"Myopathies of systemic disease\", section on 'Hypokalemic myopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"       \"Clinical manifestations of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link\">",
"       \"Hypokalemic periodic paralysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"       \"Hyperkalemic periodic paralysis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Calcium disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"       \"Clinical manifestations of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations of hypercalcemia\", section on 'Musculoskeletal symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Magnesium and phosphate disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"       \"Signs and symptoms of magnesium depletion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link\">",
"       \"Signs and symptoms of hypophosphatemia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Muscle weakness usually does not occur at potassium concentrations above 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    if hypokalemia develops slowly, but significant weakness may occur with sudden decreases. Weakness usually begins with the lower extremities, progresses to the trunk and upper extremities, and can worsen to the point of paralysis. Patients with renal dysfunction can develop hyperkalemia that manifests initially as weakness and may deteriorate into a life-threatening arrhythmia if untreated.",
"   </p>",
"   <p>",
"    Endocrine abnormalities, such as thyrotoxicosis, may also cause periodic paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Life-threatening causes of generalized weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief list of several important causes of generalized weakness is provided here to assist with the differential diagnosis and to allow ready access to additional information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis &ndash; Among other symptoms, malaise and generalized weakness may be a manifestation of sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute coronary syndrome (ACS) &ndash; A significant percentage of elderly patients with ACS complain only of generalized weakness. Diabetics and women may also complain of weakness rather than chest discomfort when experiencing an ACS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"       \"Overview of the acute management of ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carbon monoxide (CO) poisoning &ndash; The clinical findings of CO poisoning are highly variable and largely nonspecific. Moderately or mildly CO-intoxicated patients often present with constitutional symptoms, including headache (the most common presenting symptom), malaise, nausea, and dizziness, and may be misdiagnosed with acute viral syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adrenal insufficiency &ndash; Patients with chronic, progressive adrenal insufficiency most often develop the following symptoms: chronic malaise, lassitude, fatigue that is worsened by exertion and improved with bed rest, weakness that is generalized (ie, not limited to particular muscle groups), anorexia, and weight loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"       \"Clinical manifestations of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other neurologic causes of acute weakness",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple sclerosis (MS) &ndash; There are no clinical findings that are unique to MS, but some are highly characteristic of the disease (",
"      <a class=\"graphic graphic_table graphicRef63940 \" href=\"UTD.htm?21/53/22363\">",
"       table 4",
"      </a>",
"      ) while others are more common during initial presentation (",
"      <a class=\"graphic graphic_table graphicRef61789 \" href=\"UTD.htm?33/55/34684\">",
"       table 5",
"      </a>",
"      ). The typical patient presents as a young adult with two or more clinically distinct episodes of CNS dysfunction with at least partial resolution.",
"     </li>",
"     <li>",
"      Hemiplegic migraine &ndash; This uncommon migraine variant is characterized by unilateral motor and sensory symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postictal (Todd's) paralysis &ndash; Generalized or complex partial seizures may be followed by a focal motor deficit that can persist for hours and is often related to a structural abnormality of the brain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other medical causes of generalized weakness",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothyroidism &ndash; Many of the manifestations of hypothyroidism reflect one of two changes induced by lack of thyroid hormone (",
"      <a class=\"graphic graphic_table graphicRef62676 \" href=\"UTD.htm?41/41/42651\">",
"       table 6",
"      </a>",
"      ). The first is a generalized slowing of metabolic processes. This can lead to fatigue, slow movement and slow speech, cold intolerance, constipation, delayed relaxation of deep tendon reflexes, and bradycardia. The second is accumulation of matrix glycosaminoglycans in tissues, which can lead to coarse hair and skin, puffy facies, enlargement of the tongue, and hoarseness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection &ndash; Occult infection, particularly in elderly patients, may manifest as malaise and generalized weakness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42138?source=see_link\">",
"       \"Medical care of the nursing home patient in the United States\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia &ndash; The differential diagnosis of anemia is broad, but the presentation often includes progressive weakness and pallor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dehydration or hypovolemia &ndash; Hypovolemia, often as a result of vomiting, diarrhea, or diuretics, can cause generalized weakness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presyncope &ndash; Patients with acute episodes of weakness may describe a sensation of \"nearly fainting.\" Determining the presence of a cardiac cause is of particular importance in the emergency department. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"       \"Approach to the patient with dizziness\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"       \"Approach to the adult patient with syncope in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications &ndash; Many medications, in isolation or combination, and illicit drugs can cause weakness. Common culprits include beta blockers, diuretics, laxatives, chemotherapeutic agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , opioids, and alcohol. Some agents may have direct toxic effects on muscle, including glucocorticoids, statins, antimalarial drugs, antipsychotic drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , antiretrovirals, alcohol, and cocaine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rheumatologic disease &ndash; Weakness is a common feature of rheumatologic disease. As examples, fatigue is the most common complaint in patients with systemic lupus erythematosus, occurring in over 80 percent of patients, and a common complaint among those with rheumatoid arthritis. Polymyalgia rheumatica, which can be associated with the vision-threatening condition of temporal arteritis, can present with generalized weakness and myalgias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult infection, metabolic disorders, stroke, and medication related problems are common causes of weakness in the elderly. While some medications can cause myopathy directly (eg, glucocorticoids, statins), a number of medications can create problems in older patients through adverse reactions or drug interactions. Twenty percent of patients over 60 had symptoms attributable to prescription medications in one study of patients with a chief complaint of weakness or dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Defining weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial challenge is to determine exactly what a patient means when they complain of \"weakness.\" True weakness is the inability to perform a desired movement with normal force because of a reduction in muscle strength. While this may be due to a primary neuromuscular process, more often the complaint represents malaise associated with a medical illness. Such an illness may include virtually the entire spectrum of medical pathology, including such serious conditions as sepsis, acute coronary syndrome, heart failure, dehydration, severe hypokalemia, adrenal insufficiency, or hypothyroidism. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis of acute weakness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other important definitions include paresis, which indicates partial or complete paralysis, and plegia, which indicates total loss of muscle contraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Approach to the history",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a neurologic or neuromuscular problem is suspected, an algorithmic approach based upon a thorough history and examination facilitates neuroanatomic localization of the pathology (",
"    <a class=\"graphic graphic_algorithm graphicRef54645 \" href=\"UTD.htm?18/15/18676\">",
"     algorithm 1",
"    </a>",
"    ). Exclusion of potentially life-threatening and other serious illness at each neuroanatomic site is an important part of this approach (",
"    <a class=\"graphic graphic_table graphicRef61895 \" href=\"UTD.htm?22/9/22685\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Assessment of life threatening illness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The history should include a description of the distribution of weakness (eg, bilateral hands) and its manifestations (eg, difficulty with fine motor tasks), the period over which symptoms developed, and clinical features associated with the weakness (eg, aphasia, diplopia). The important initial tasks are to determine whether the weakness is unilateral or bilateral and whether signs associated with central neurologic involvement are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Unilateral weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important questions to consider when evaluating a patient with unilateral weakness include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are cortical signs present, such as aphasia, neglect, agnosia, or apraxia?",
"     </li>",
"     <li>",
"      Is the face involved (eg, facial droop)?",
"     </li>",
"     <li>",
"      Is there a myotomal pattern to the distribution of weakness?",
"     </li>",
"     <li>",
"      Is the description of weakness consistent with a particular peripheral nerve?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally, unilateral facial weakness implies a lesion above the spinal cord, either in the brainstem or cortex. Other associated cortical features can help localize pathology in one of the two cerebral hemispheres (",
"    <a class=\"graphic graphic_algorithm graphicRef54645 \" href=\"UTD.htm?18/15/18676\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the case of isolated extremity weakness without cortical signs, the clinician uses knowledge of common radicular and peripheral nerve entrapment syndromes to identify the problem. A localized process (eg, weakness and paresthesias limited to one or two fingers) suggests peripheral nerve entrapment, although distinguishing spinal from peripheral nerve entrapment can be challenging in some instances. Familiarity with cervical and lumbosacral dermatomes and myotomes helps with recognition of spinal nerve root compression, and may help to differentiate this from peripheral pathology (",
"    <a class=\"graphic graphic_table graphicRef74632 \" href=\"UTD.htm?0/56/908\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64209 \" href=\"UTD.htm?4/31/4605\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75974 \" href=\"UTD.htm?22/51/23355\">",
"     table 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bilateral weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important questions to consider when evaluating a patient with bilateral weakness include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is mental status depressed?",
"     </li>",
"     <li>",
"      Which limbs are involved?",
"     </li>",
"     <li>",
"      Is there sensory involvement? If so, is a sensory level deficit suggested?",
"     </li>",
"     <li>",
"      Is there bladder involvement?",
"     </li>",
"     <li>",
"      Does weakness primarily involve proximal or distal muscles?",
"     </li>",
"     <li>",
"      Are there bulbar signs (involving tongue, jaw, face, or larynx)?",
"     </li>",
"     <li>",
"      Does the degree of weakness fluctuate?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A central nervous system (CNS) lesion causing bilateral weakness is usually accompanied by diminished mental status, unless the lesion lies in the spinal cord. The presence of bladder dysfunction or a sensory deficit below a discrete dermatomal level suggests a myelopathy.",
"   </p>",
"   <p>",
"    The proximal motor weakness typically found early in the course of a myopathy is suggested by difficulty walking up stairs or getting up from a chair, if the lower limbs are involved, or difficulty with overhead activities (eg, combing hair), if the upper extremities are involved.",
"   </p>",
"   <p>",
"    Symptoms associated with disease at the neuromuscular junction include visual symptoms, particularly ptosis and diplopia, and bulbar signs. Bulbar muscle weakness may manifest as nasal speech, coughing, or lingual dysarthria. A fatiguing pattern to weakness, suggested by worsening with repeated activity (eg, chewing), suggests myasthenia gravis.",
"   </p>",
"   <p>",
"    Periodic paralysis due to imbalances in potassium regulation (or other electrolyte abnormalities) is suggested by acute attacks of weakness lasting a few hours to a couple of days that spontaneously resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neurologic examination, with careful attention to strength testing and deep tendon reflexes, is necessary in all patients who complain primarily of acute weakness. A more detailed examination must be performed in patients with symptoms suggestive of a central process (eg, dysarthria, oculomotor or visual dysfunction, ataxia). The detailed examination should include careful assessment of cranial nerve and motor function and specific testing for findings associated with serious causes of weakness (eg, pronator drift). Performance of the neurologic examination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Motor neuron findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition and distinction between upper motor neuron (UMN) or lower motor neuron (LMN) signs is important when determining the nature of a weakness syndrome (",
"    <a class=\"graphic graphic_table graphicRef56458 \" href=\"UTD.htm?1/55/1915\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62641 \" href=\"UTD.htm?17/1/17432\">",
"     figure 3",
"    </a>",
"    ). How to make this distinction between UMN and LMN lesions and localize spinal cord lesions are discussed in detail separately, but a few highlights are described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H62#H62\">",
"     \"The detailed neurologic examination in adults\", section on 'Upper versus lower motor neuron lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of UMN disease include spasticity (ie, increased muscle tone), hyperreflexia, and an extensor plantar response (Babinski reflex). These findings are absent in pure peripheral disease. However, hyporeflexia and flaccid paralysis may occur with acute central lesions, with hyperreflexia and spasticity developing later. An example of UMN disease encountered in the ED is the patient who presents with acute spinal cord transection from trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of LMN disease include decreased muscle tone and hyporeflexia. The Babinski reflex is absent. If weakness is bilateral and signs of LMN disease are present, the major disorders to consider are neuropathies, myopathies, and disorders of the neuromuscular junction (NMJ). The distinguishing features of these processes are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75434 \" href=\"UTD.htm?14/42/15019\">",
"     table 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neuropathies tend to involve distal muscle groups, while myopathies more often involve proximal muscles. Reflexes are decreased in neuropathies, but may be present, decreased, or absent with myopathies. Myopathies may have associated myalgias but sensory symptoms are generally absent. The most distinguishing feature of neuromuscular junction disease is early involvement of the bulbar musculature (ie, tongue, jaw, face, and larynx).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Strength testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strength testing is central to the examination of the weak patient. Clinicians should employ the standardized motor grading scale agreed upon by the Medical Research Council (",
"    <a class=\"graphic graphic_table graphicRef77388 \" href=\"UTD.htm?9/58/10155\">",
"     table 13",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/4\">",
"     4",
"    </a>",
"    ]. Using historical features as a guide, first try to identify if there is a pattern to the weakness. Hemiparesis suggests a hemispheric lesion; paraparesis suggests a spinal cord lesion. Peripheral nerve disease, notably Guillain-Barr&eacute; syndrome, can also cause paraparesis.",
"   </p>",
"   <p>",
"    If the history suggests a proximal pattern of weakness, such as difficulty walking up stairs or difficulty standing from a chair, seek to distinguish proximal from distal muscle weakness. Proximal weakness suggests a myopathic process rather than a neuropathy. Strength testing of specific muscle groups is useful when assessing isolated extremity weakness (",
"    <a class=\"graphic graphic_figure graphicRef58656 \" href=\"UTD.htm?10/47/10995\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64884 \" href=\"UTD.htm?30/36/31297\">",
"     figure 5",
"    </a>",
"    ). If pathology at the NMJ is suspected, oculomotor and bulbar testing are critical. Assess extraocular movements, eyelid strength, masseter muscle strength, facial expression, and palatal movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Reflex testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflex testing aids in the diagnosis and the localization of nerve lesions (",
"    <a class=\"graphic graphic_table graphicRef74632 \" href=\"UTD.htm?0/56/908\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75645 \" href=\"UTD.htm?7/31/7676\">",
"     table 14",
"    </a>",
"    ). Tendon jerks are graded using a standard scale, with zero representing absence and four representing hyperactivity with clonus (",
"    <a class=\"graphic graphic_table graphicRef82522 \" href=\"UTD.htm?8/23/8571\">",
"     table 15",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lesions in one cerebral hemisphere generally result in hyperreflexia of the affected side due to disruption of the UMN. Interruption of the corticospinal tracts bilaterally generally causes symmetrical hyperreflexia and extensor plantar responses (positive Babinski). A spinal cord lesion is the most common cause of such findings, but in rare instances, bilateral cerebral hemisphere damage or brainstem disease may be present.",
"   </p>",
"   <p>",
"    Nerve root compression most often causes unilateral absence of a specific lower extremity reflex. As an example, unilateral loss of the ankle jerk suggests a lesion at the S1 nerve root.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fatigability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigability describes normal strength during initial testing that decreases significantly as testing continues. It is characteristic of myasthenia gravis. Maneuvers, such as the ice test or Tensilon test can be performed to diagnose NMJ pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Bedside tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Sensation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the presence, pattern, or absence of sensory symptoms and signs can be helpful in confirming the neuroanatomic level producing weakness, the subjective nature of sensory findings makes interpretation challenging. Classically, a cortical lesion causes relatively mild hemisensory loss, which affects touch and proprioception more than pain. The patient may simply describe this as their arm or leg \"feeling funny.\" A spinal cord lesion often affects sensation bilaterally, with the upper level of the sensory loss defining the lesion level.",
"   </p>",
"   <p>",
"    In contrast, cervical central cord lesions most commonly produce a \"cape\" sensory loss over the shoulders affecting pain and temperature sensation, but spares vibration and proprioception (so-called \"dissociated\" sensory loss). Lesions of the conus medullaris or cauda equina produce loss of sensation in the perineum. When the lateral half of the spinal cord is damaged (Brown-Sequard syndrome) proprioception and vibration are lost ipsilateral to the lesion, while pain and temperature sensation are lost on the contralateral side.",
"   </p>",
"   <p>",
"    In the case of more localized sensory loss in a limb, familiarity with dermatomes and peripheral nerve sensory distributions helps to differentiate a spinal root lesion from that of a peripheral nerve (",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54042 \" href=\"UTD.htm?41/32/42505\">",
"     figure 6",
"    </a>",
"    ). The absence of sensory symptoms in such cases suggests the weakness stems from a myopathy or NMJ disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of diagnostic testing performed on a weak patient in the emergency department (ED) varies depending upon the differential diagnosis and the potential pace of deterioration of any neuromuscular process being considered. As examples, a potentially septic patient with no obvious source of infection undergoes extensive diagnostic testing, a patient with a possible acute ischemic stroke requires an emergent head computed tomography (CT), and most patients with a presumed peripheral nerve entrapment require no diagnostic testing in the ED.",
"   </p>",
"   <p>",
"    For many patients with generalized weakness, it is reasonable to obtain a hemoglobin concentration and electrolyte panel testing. A hemoglobin measurement identifies anemia while a standard electrolyte panel enables assessment of serum glucose, potassium, sodium, and renal function. An electrocardiogram (ECG) is a reasonable screening tool in elderly patients with generalized weakness and in patients with an abnormal potassium or calcium level. Beyond these baseline tests, a focused differential diagnosis determines further testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry provides a reasonable index of oxygenation, but is insensitive for identifying patients with significant neuromuscular disease. Arterial blood gas measurement may not be helpful in establishing the likelihood of imminent respiratory failure, because the pCO2 can rise precipitously as diaphragmatic and intercostal muscle weakness progresses with neuromuscular disease.",
"   </p>",
"   <p>",
"    Patients with such diseases commonly lose tidal volume before upper airway weakness develops, resulting in an increased respiratory rate to maintain minute ventilation. In such cases, the pCO2 may remain normal or low until the tidal volume becomes dangerously low.",
"   </p>",
"   <p>",
"    For this reason, selected pulmonary function tests (PFTs) are needed to determine the degree of respiratory compromise and to aid in the decision to intubate patients with suspected neuromuscular disease, such as Guillain-Barr&eacute; syndrome (GBS) or myasthenia gravis (MG). As always, patients determined to be in respiratory distress or in danger of imminent respiratory compromise are intubated based upon clinical assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific tests that can be used to assess respiratory function are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Neuroradiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroradiological diagnostic testing may be useful depending upon where a lesion is suspected. A head CT without contrast is performed when a cortical process must be assessed. CT identifies acute hemorrhage, mass lesions, and cerebral edema in the great majority of cases, but may appear normal in the early stages of ischemic stroke. A head CT with contrast is obtained if an intracranial tumor or certain infections (eg, toxoplasmic encephalitis) are suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcortical lesions, such as those in the brainstem, are best seen with MRI; this portion of the brain is poorly visualized on CT due to bone artifact from the base of the skull.",
"   </p>",
"   <p>",
"    MRI is the imaging modality of choice if a nerve root or spinal cord process is suspected. CT scanning with myelography can be useful for diagnosing many myelopathic processes if MRI is unavailable or there is a contraindication to its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain chest x-ray may be helpful if a malignancy, or related complication, is suspected. Such circumstances might include looking for a Pancoast tumor in a patient with a brachial plexopathy or a small-cell lung cancer in a patient with Lambert-Eaton syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"     \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cerebral spinal fluid (CSF) analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF analysis is indicated when Guillain-Barr&eacute; syndrome (GBS), myelitis, or demyelinating peripheral neuropathy is suspected. In GBS, the CSF typically reveals an elevated protein with a normal white blood cell count. However, a normal CSF is found is as many as one-third of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With a myelitis, CSF analysis is normal in approximately half of patients. In the other half, it may reveal an elevated protein or moderate lymphocytosis, but the glucose concentration remains normal. A process such as an inflammatory demyelinating peripheral neuropathy generally demonstrates elevated CSF protein. A lymphocytic pleocytosis is often present if disease is related to HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=see_link\">",
"     \"Diagnosis, treatment and prognosis of HIV-associated neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Tensilon test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more invasive and potentially hazardous test that may aid in the diagnosis of myasthenia gravis is the patient's response to a short-acting anticholinesterase agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    ). This agent blocks acetylcholine esterase, allowing sufficient acetylcholine to remain within the synaptic cleft to stimulate the decreased number of postsynaptic binding sites, thereby improving symptoms. Performance of the test is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Tensilon test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    False-positive responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"     edrophonium",
"    </a>",
"    chloride have been reported in Amyotrophic lateral sclerosis, Lambert-Eaton myasthenic syndrome, GBS, wound botulism, cavernous sinus lesions, polymyositis, and alcoholic myositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatine phosphokinase (CPK) is a sensitive marker for muscle damage and may be a useful screening test when an acute myopathy is considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF LIFE THREATENING ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate life threats from acute neuromuscular weakness include inability to protect or maintain the airway, respiratory failure from thoracic and diaphragmatic muscle weakness, and circulatory collapse from autonomic instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergency clinician's first task is to identify patients at risk for acute respiratory failure. Signs of respiratory distress in patients with neuromuscular weakness can include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid, shallow breathing",
"     </li>",
"     <li>",
"      Poor respiratory effort; use of accessory muscles",
"     </li>",
"     <li>",
"      Difficulty swallowing; inability to handle secretions",
"     </li>",
"     <li>",
"      Inability to lift head off bed",
"     </li>",
"     <li>",
"      Weak, ineffective cough",
"     </li>",
"     <li>",
"      Weak or muffled voice",
"     </li>",
"     <li>",
"      Depressed mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often, the first and most apparent sign is tachypnea. Patients with progressive generalized neuromuscular weakness commonly begin to lose tidal volume before upper airway weakness develops, resulting in an increased respiratory rate to maintain minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to secure the airway of patients with respiratory difficulty is made primarily on clinical grounds. However, measurement of simple bedside pulmonary tests, end-tidal carbon dioxide (EtCO2), and arterial oxygen saturation (SpO2) may provide insight into the patient's respiratory status. Note that patients may be able to maintain CO2 levels in the normal or even low range despite dangerously low tidal volumes. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Pulmonary function testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Airway assessment and management are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performing rapid sequence intubation (RSI), it is important in some settings to avoid depolarizing neuromuscular blocking agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    ) and instead to use a nondepolarizing neuromuscular blocking agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/7\">",
"     7",
"    </a>",
"    ]. This avoids the risk of hyperkalemic respiratory arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests that neurologic injury markedly exaggerates the potassium release associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/8\">",
"     8",
"    </a>",
"    ]. A conservative estimate is that the initial threat of such increased potassium release develops three days after complete denervation or seven days after partial denervation.",
"   </p>",
"   <p>",
"    The risk of a hyperkalemic response is greatest among particular patients with neuromuscular weakness, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Denervating injuries (eg, stroke, spinal cord injury) of greater than three days duration",
"     </li>",
"     <li>",
"      Denervating diseases (eg, Guillain-Barr&eacute; syndrome with symptoms over three days, multiple sclerosis, amyotrophic lateral sclerosis, transverse myelitis with symptoms over three days)",
"     </li>",
"     <li>",
"      Inherited myopathies (eg, Duchenne's muscular dystrophy)",
"     </li>",
"     <li>",
"      Prolonged immobilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    is safe in myasthenia gravis, but increased doses are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link&amp;anchor=H5#H5\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Clinical use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction accompanies some polyneuropathies and disorders of the neuromuscular junction, and can also occur in patients with generalized weakness due to systemic infection or acute coronary syndrome. Autonomic instability in the setting of neurologic weakness typically manifests initially as a hypersympathetic state, heralded by sinus tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/6\">",
"     6",
"    </a>",
"    ]. Thereafter, fluctuation in the heart rate and blood pressure occur. Treatment is largely supportive. Rarely, bradycardia can occur, which may require temporary pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Critical diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;With severely ill patients, the clinician must simultaneously assess the patient for life-threatening signs, begin resuscitative measures as indicated, develop a preliminary differential diagnosis, and initiate an appropriate work-up. An overview of the differential diagnosis for acute weakness is provided. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis of acute weakness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Important neurologic diagnoses to consider in the weak patient with respiratory distress or hemodynamic instability include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic or hemorrhagic stroke (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      CNS infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal cord injury (including compression) or inflammation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"       \"Disorders affecting the spinal cord\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myasthenic crisis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important causes of generalized weakness to consider in the patient with respiratory distress or hemodynamic instability include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute cardiovascular disease (eg, coronary syndrome, decompensated heart failure)",
"     </li>",
"     <li>",
"      Intoxication or poisoning (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"       \"General approach to drug poisoning in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe electrolyte abnormalities (eg, hypokalemia, hyperkalemia)",
"     </li>",
"     <li>",
"      Endocrine crisis (eg, diabetic ketoacidosis, hypoadrenal (Addisonian) crisis, myxedema coma, thyrotoxicosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Algorithmic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once life-threatening problems have been addressed or ruled out, the clinician approaches the patient with objective weakness in a systematic manner, as outlined in the accompanying algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef54645 \" href=\"UTD.htm?18/15/18676\">",
"     algorithm 1",
"    </a>",
"    ). The first important step in this approach is to determine whether the weakness is unilateral (asymmetric) or bilateral (symmetric), and to look closely for signs of central neurologic involvement.",
"   </p>",
"   <p>",
"    In the assessment of both unilateral and bilateral weakness, it is helpful to begin cephalad and centrally and then progress caudad and peripherally. This approach provides a reliable framework for neuroanatomic localization and accurate diagnosis.",
"   </p>",
"   <p>",
"    If unilateral weakness is identified, look carefully for signs suggestive of cortical, subcortical (lacunar), or brainstem lesions. If these are absent, a peripheral process (radiculopathy, plexopathy, or peripheral nerve injury) most likely accounts for the patient's symptoms.",
"   </p>",
"   <p>",
"    If bilateral weakness is identified, consider the patient's mental status and look carefully for signs of upper or lower motor neuron lesions and associated abnormalities. The constellation of examination findings should allow approximate identification of the site of the lesion and determination of the need for imaging studies, specialist consultation, and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Unilateral weakness",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Cortical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient complaining of unilateral weakness, first inquire whether the limbs and lower face on the same side are involved. If so, a lesion exists in the contralateral cerebral hemisphere.",
"   </p>",
"   <p>",
"    To further pinpoint the lesion's location, look closely for cortical signs, such as an aphasia, hemineglect, gaze preference, visual deficits, or apraxia. Aphasia usually corresponds to a left hemispheric stroke, since the left cerebral hemisphere controls language function in the majority of both right-handed and left-handed individuals. A nonfluent (Broca's) aphasia often accompanies a right hemiplegia of cortical origin, since the motor cortex is in close proximity to Broca's area. Several tables to assist in the identification of stroke are included (",
"    <a class=\"graphic graphic_table graphicRef75487 \" href=\"UTD.htm?27/15/27900\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69630 \" href=\"UTD.htm?31/10/31914\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"UTD.htm?39/33/40477\">",
"     table 16",
"    </a>",
"    ). Detailed discussions of the clinical manifestations and acute management of stroke are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left-sided neglect is a cortically mediated deficit that usually occurs in right hemispheric strokes. The centers controlling conjugate gaze are located in each frontal lobe. If one center is damaged, the unopposed action of the other causes the eyes to deviate toward the side of the lesion and away from the hemiplegia.",
"   </p>",
"   <p>",
"    Contralateral homonymous hemianopia is another important ocular finding that occurs in association with a lesion anywhere along the hemispheral visual pathways. Cortical sensory loss accompanies the hemiplegia if the sensory cortex, located across the Rolandic fissure, is involved. Rarely, a cortical infarction causes pure motor hemiparesis, with no cortical findings other than hemiparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=see_link\">",
"     \"Homonymous hemianopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Lacunar syndromes and basal ganglia lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions in the subcortical cerebral hemisphere, namely deep hemorrhages due to hypertension and ischemic lacunar strokes, can cause weakness. Importantly, cortical deficits are absent (",
"    <a class=\"graphic graphic_table graphicRef67341 \" href=\"UTD.htm?36/36/37451\">",
"     table 17",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lacunar infarcts are small, deep cerebral infarcts due almost exclusively to disease of the perforating arterioles. They account for about one quarter of strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/10\">",
"     10",
"    </a>",
"    ]. Each of the classically described lacunar syndromes has also been associated with nonischemic lesions, including hemorrhage and tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Brainstem processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness syndromes referable to the brainstem may present with \"crossed\" findings (ipsilateral cranial nerve weakness and contralateral hemiparesis) due to lesions involving cranial nerve nuclei or their tracts and the corticospinal tract before its decussation. However, this is often not the case. As an example, a lacunar stroke in the pons can appear indistinguishable clinically (hemiparesis, ataxia) from a lacunar stroke affecting the internal capsule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"     \"Posterior circulation cerebrovascular syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Brown-Sequard syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most myelopathies present with bilateral weakness, even if the distribution is patchy. The main exception is Brown-Sequard syndrome. In this syndrome, involvement of either lateral hemisection of the spinal cord results in ipsilateral hemiplegia or monoplegia, ipsilateral loss of vibration and proprioception, and contralateral loss of pain and temperature below the level of the lesion. Brown-Sequard syndrome is typically caused by penetrating trauma, but idiopathic cases from preexisting dural defects have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H18#H18\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Brown-Sequard (hemi-cord) syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Radiculopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal nerve roots mark the beginning of the peripheral nervous system. Radiculopathies are any disease or condition affecting the spinal nerve roots. These syndromes typically present as pain in a dermatomal distribution. Weakness in a myotomal distribution can occur but is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/15\">",
"     15",
"    </a>",
"    ]. Most spinal nerve compression syndromes usually involve either the cervical or lumbosacral region (",
"    <a class=\"graphic graphic_table graphicRef74632 \" href=\"UTD.htm?0/56/908\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64209 \" href=\"UTD.htm?4/31/4605\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75974 \" href=\"UTD.htm?22/51/23355\">",
"     table 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\", section on 'Sciatica'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\", section on 'Cauda equina'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Plexopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best way to diagnose a plexopathy (eg, brachial plexopathy, thoracic outlet syndrome, lumbar plexopathy) is to identify a motor and sensory deficit in a limb that involves more than one spinal or peripheral nerve. Lower motor neuron (LMN) signs are more prominent than sensory findings. Causes include trauma, radiation therapy, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of cancer pain syndromes\", section on 'Plexopathies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Lumbosacral plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Peripheral nerve injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerve injuries typically involve neurapraxias, implying a temporary insult to the nerve that resolves when compression is relieved. The most common sites for such neurapraxias are narrow passageways in which the nerve moves during flexion and extension of the neighboring joint. Carpal tunnel syndrome is a classic example. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Bilateral Weakness",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Cortical or brainstem lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lesion in the central nervous system causing bilateral weakness is usually accompanied by diminished mental status, unless the pathology resides in the spinal cord. The simultaneous occurrence of bilateral, symmetric lesions of the motor cortex is highly unlikely, but a lesion in the interhemispheric fissure, such as a parasagittal meningioma, could result in paraparesis simulating a spinal cord lesion. This is because the areas involved with lower extremity function lie on the medial sides of the motor strip of each cerebral cortex and face each other in the interhemispheric fissure.",
"   </p>",
"   <p>",
"    A small lesion at the decussation of the pyramids (cruciate paralysis of Bell) can cause bilateral paralysis of the upper extremities, with no involvement of the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Such lesions are rare and generally result from trauma.",
"   </p>",
"   <p>",
"    The \"locked-in syndrome\" is a devastating central process that causes quadriparesis and mutism, but leaves consciousness intact [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/22\">",
"     22",
"    </a>",
"    ]. In this syndrome, a ventral pontine lesion causes quadriplegia, facial weakness, lateral gaze weakness, and dysarthria. Vertical gaze and eyelid opening are preserved. In the ED it is critical to distinguish between a comatose patient and one with locked-in syndrome, who may be a candidate for endovascular fibrinolysis to recanalize a basilar artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/63/34807?source=see_link\">",
"     \"Locked-in syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Myelopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontraumatic myelopathies (diseases of the spinal cord) typically present with bilateral extremity weakness and sensory deficits. Leg weakness is the most common symptom, but arm weakness can occur when the cervical spinal cord is involved. Bowel and bladder symptoms may be present due to interruption of the descending upper motor neuron pathways, which control the urinary and rectal sphincters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/24\">",
"     24",
"    </a>",
"    ]. Impotence or priapism may occur. Disturbances in autonomic function, such as loss of sweating, trophic skin changes, loss of temperature control, and vasomotor instability, can occur below the level of the lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of a myelopathy can help to determine its cause. Without a history of trauma, acute disruptions suggest vascular pathology; subacute or chronic development of symptoms suggests an inflammatory lesion.",
"   </p>",
"   <p>",
"    Myelopathies generally present with some signs of upper motor neuron (UMN) disease. However, the traumatic and vascular processes that cause myelopathy often produce a flaccid areflexic paralysis initially. Over several days, the motor findings become characteristic of an UMN paralysis, with hyperreflexia and bilateral extensor plantar responses (positive Babinski test). Discrete dermatomal sensory loss may not be obvious on examination.",
"   </p>",
"   <p>",
"    Myelopathy is generally diagnosed by history and physical examination, and confirmed by MRI. Emergent consultation with a spine surgeon is essential if an epidural compression syndrome is suspected, since prognosis depends upon the patient's neurologic function at the time of intervention. Specifically, among patients with epidural compression due to a malignancy, those who are ambulatory generally remain so, while only ten percent of patients who are paraplegic at the time of surgery regain ambulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h3\">",
"     Polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyneuropathies (eg, Guillain-Barr&eacute; syndrome) manifest both motor and sensory symptoms, unlike myopathies and NMJ disorders. Weakness is due to the large number of nerves involved. Distal power is reduced most dramatically. Deep tendon reflexes are characteristically diminished and vibratory sense is invariably lost distally. Paresthesias often herald the weakness from a peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Neuromuscular junction processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting signs of disease at the neuromuscular junction (NMJ) are ocular (ptosis, diplopia) and bulbar abnormalities (dysarthria, dysphagia). Limb weakness, when it occurs, tends to involve the upper extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41688?source=see_link\">",
"     \"Overview of neuromuscular junction toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myasthenia gravis (MG) is a common example and diagnosis is straightforward in a patient with ocular, bulbar, and limb weakness that fluctuates throughout the day and improves with rest. The patient with milder disease or disease limited to a specific muscle group can present a diagnostic dilemma. Provocative maneuvers can help make the diagnosis in such cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h3\">",
"     Myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathies result from disease within the myocyte (eg, muscular dystrophy) or as a manifestation of a systemic disorder (eg, metabolic or inflammatory polymyopathies). Sensory abnormalities are usually absent in patients with generalized myopathies, while myalgias may occur in those with inflammatory myopathies. Weakness typically begins in the proximal muscles and extends distally thereafter. Deep tendon reflexes are often maintained until severe weakness develops. Hence, hyporeflexia cannot be relied upon to distinguish myopathies from other neuromuscular processes. Although atrophy is a characteristic finding, it is not apparent initially when large muscle groups are involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14137?source=see_link\">",
"     \"Myopathies of systemic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myotonic muscular dystrophy type 1 presents with distal muscle involvement. Myotonic muscular dystrophy type 2 (ie, proximal myotonic dystrophy) most often presents with weakness in the muscles of the hip girdle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a new, undiagnosed process causing weakness that is suspected to be neuromuscular or toxin mediated should be admitted. Consultation with neurology and toxicology services is obtained as needed. Any patient at risk of developing respiratory or cardiovascular instability should be admitted to a highly monitored setting, typically an intensive care unit.",
"   </p>",
"   <p>",
"    Patients without a clear diagnosis but at risk for a polyneuropathy such as GBS should generally be admitted. Patients who insist upon discharge must be advised to return to the ED immediately if worsening weakness or difficulty breathing develops, and an adult capable of providing assistance should be at home with them.",
"   </p>",
"   <p>",
"    Patients who appear well and will be discharged but in whom potentially dangerous diagnoses cannot be definitively excluded should be provided with written discharge instructions that include specific guidance about danger signs to look for and when and where to return should these develop. As an example, most patients with GBS are initially misdiagnosed and discharged home [",
"    <a class=\"abstract\" href=\"UTD.htm?26/58/27562/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients complaining of weakness do not have a neurologic emergency or rapidly progressive neuromuscular disease and can be safely discharged home after a thorough, systematic assessment has ruled out pathology requiring admission. Discharged patients should be referred to a specialist or their primary care provider for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weakness is a common, nonspecific emergency department (ED) complaint that encompasses a broad differential diagnosis including neurologic and non-neurologic diseases. In the elderly, infection, cardiovascular disease, and dehydration must be considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis of acute weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of potentially life-threatening neurologic and neuromuscular processes requires a systematic, anatomic approach based upon a careful history, physical examination, and in some cases, imaging studies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The emergency clinician's first responsibility is to rule out life-threatening or permanently disabling causes of weakness that require urgent treatment. The immediate life threats from acute neuromuscular weakness include inability to protect or maintain the airway, respiratory failure from thoracic and diaphragmatic muscle weakness, and circulatory collapse from autonomic instability. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Assessment of life threatening illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients diagnosed with an acute ischemic stroke should be rapidly evaluated to determine appropriate treatment with systemic thrombolytic therapy or emergency revascularization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"       \"Initial assessment and management of acute stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once life-threatening problems have been addressed or ruled out, the clinician approaches the patient with objective weakness in a systematic manner, as outlined in the accompanying algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef54645 \" href=\"UTD.htm?18/15/18676\">",
"       algorithm 1",
"      </a>",
"      ). The first important step in this approach is to determine whether the weakness is unilateral (asymmetric) or bilateral (symmetric), and to look closely for signs of central neurologic involvement.",
"     </li>",
"     <li>",
"      When assessing acute weakness, it is helpful to begin cephalad and centrally and then progress caudad and peripherally. This approach provides a reliable framework for neuroanatomic localization and accurate diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If unilateral weakness is identified, look carefully for signs suggestive of cortical, subcortical (lacunar), or brainstem lesions. If these are absent, a peripheral process (radiculopathy, plexopathy, or peripheral nerve injury) most likely accounts for the patient's symptoms.",
"     </li>",
"     <li>",
"      If bilateral weakness is identified, consider the patient's mental status and look carefully for signs of upper or lower motor neuron lesions and associated abnormalities. The constellation of examination findings should allow approximate identification of the site of the lesion and determination of the need for imaging studies, specialist consultation, and treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/1\">",
"      Hughes RA, Cornblath DR. Guillain-Barr&eacute; syndrome. Lancet 2005; 366:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/2\">",
"      McGillicuddy DC, Walker O, Shapiro NI, Edlow JA. Guillain-Barr&eacute; syndrome in the emergency department. Ann Emerg Med 2006; 47:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/3\">",
"      Skiendzielewski JJ, Martyak G. The weak and dizzy patient. Ann Emerg Med 1980; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Research Council. Aids to the Investigation of Peripheral Nerves, Crown Publishing, London 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/5\">",
"      Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med 1991; 324:1445.",
"     </a>",
"    </li>",
"    <li>",
"     Juel VC, Bleck TP. Neuomuscular disorders in critical care. In: Textbook of Critical Care, Grenvik A, Ayres SM, Holbrook PR, Shoemaker WC.  (Eds), WB Saunders, Philadelphia 2000. p.1886.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/7\">",
"      Orebaugh SL. Succinylcholine: adverse effects and alternatives in emergency medicine. Am J Emerg Med 1999; 17:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/8\">",
"      Tobey RE, Jacobsen PM, Kahle CT, et al. The serum potassium response to muscle relaxants in neural injury. Anesthesiology 1972; 37:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/9\">",
"      Fisher CM, Curry HB. Pure motor hemiplegia. Trans Am Neurol Assoc 1964; 89:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/10\">",
"      Gan R, Sacco RL, Kargman DE, et al. Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology 1997; 48:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/11\">",
"      Massicotte EM, Montanera W, Ross Fleming JF, et al. Idiopathic spinal cord herniation: report of eight cases and review of the literature. Spine (Phila Pa 1976) 2002; 27:E233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/12\">",
"      Borges LF, Zervas NT, Lehrich JR. Idiopathic spinal cord herniation: a treatable cause of the Brown-Sequard syndrome--case report. Neurosurgery 1995; 36:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/13\">",
"      Wada E, Yonenobu K, Kang J. Idiopathic spinal cord herniation: report of three cases and review of the literature. Spine (Phila Pa 1976) 2000; 25:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/14\">",
"      Rumana CS, Baskin DS. Brown-Sequard syndrome produced by cervical disc herniation: case report and literature review. Surg Neurol 1996; 45:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/15\">",
"      Truumees E, Herkowitz HN. Cervical spondylotic myelopathy and radiculopathy. Instr Course Lect 2000; 49:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/16\">",
"      Argoff CA, Wheeler AH. Spinal and radicular pain disorders. Neurol Clin 1998; 16:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/17\">",
"      Chad DA, Recht LD. Neuromuscular complications of systemic cancer. Neurol Clin 1991; 9:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/18\">",
"      Newton HB. Neurologic complications of systemic cancer. Am Fam Physician 1999; 59:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/19\">",
"      Bell HS. Paralysis of both arms from injury of the upper portion of the pyramidal decussation: \"cruciate paralysis\". J Neurosurg 1970; 33:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/20\">",
"      Ladouceur D, Veilleux M, Levesque RY. Cruciate paralysis secondary to C1 on C2 fracture-dislocation. Spine (Phila Pa 1976) 1991; 16:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/21\">",
"      Marano SR, Calica AB, Sonntag VK. Bilateral upper extremity paralysis (Bell's cruciate paralysis) from a gunshot wound to the cervicomedullary junction. Neurosurgery 1986; 18:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/22\">",
"      Patterson JR, Grabois M. Locked-in syndrome: a review of 139 cases. Stroke 1986; 17:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/23\">",
"      Wijdicks EF, Nichols DA, Thielen KR, et al. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience. Mayo Clin Proc 1997; 72:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/24\">",
"      Dawson DM, Potts F. Acute nontraumatic myelopathies. Neurol Clin 1991; 9:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/25\">",
"      Helweg-Larsen S. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand 1996; 94:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/26\">",
"      Portenoy RK, Lipton RB, Foley KM. Back pain in the cancer patient: an algorithm for evaluation and management. Neurology 1987; 37:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/58/27562/abstract/27\">",
"      Massey JM. Acquired myasthenia gravis. Neurol Clin 1997; 15:577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 294 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-002C802214-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27562=[""].join("\n");
var outline_f26_58_27562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H56\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS OF ACUTE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening central causes of unilateral weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life-threatening and other serious causes of bilateral weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Brainstem stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Spinal cord disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Peripheral nerve disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neuromuscular junction disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Muscle disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Life-threatening medical causes with focal findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Life-threatening causes of generalized weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other neurologic causes of acute weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other medical causes of generalized weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Defining weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Approach to the history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Unilateral weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bilateral weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Motor neuron findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Strength testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Reflex testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fatigability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Sensation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Neuroradiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cerebral spinal fluid (CSF) analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Tensilon test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ASSESSMENT OF LIFE THREATENING ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Critical diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Algorithmic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Unilateral weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Cortical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Lacunar syndromes and basal ganglia lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Brainstem processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Brown-Sequard syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Radiculopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Plexopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Peripheral nerve injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Bilateral Weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Cortical or brainstem lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Myelopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      - Polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Neuromuscular junction processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      - Myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/294|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/15/18676\" title=\"algorithm 1\">",
"      Acute neuromusc weak algo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/294|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 1\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/36/10822\" title=\"figure 2\">",
"      Lumbosacral dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/1/17432\" title=\"figure 3\">",
"      Neuromusc motor unit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/47/10995\" title=\"figure 4\">",
"      Upper extremity nerve roots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/36/31297\" title=\"figure 5\">",
"      Lower extremity nerve roots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/32/42505\" title=\"figure 6\">",
"      Peripheral nerve innervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/10/31914\" title=\"figure 7\">",
"      Anterior circulation stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/294|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/51/27451\" title=\"table 1\">",
"      Acute stroke differential dx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43419\" title=\"table 2\">",
"      Characteristics of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/15/27900\" title=\"table 3\">",
"      Acute stroke syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/53/22363\" title=\"table 4\">",
"      Clinical features of MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/55/34684\" title=\"table 5\">",
"      Presenting symptoms in MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/41/42651\" title=\"table 6\">",
"      Symptoms and signs of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/9/22685\" title=\"table 7\">",
"      Weakness anatomic differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/56/908\" title=\"table 8\">",
"      Symptoms of cervical root lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4605\" title=\"table 9\">",
"      Lumbosacral myotomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/51/23355\" title=\"table 10\">",
"      Lumbosacral radiculopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/55/1915\" title=\"table 11\">",
"      Motor neuron signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/42/15019\" title=\"table 12\">",
"      Neuro vs myopathy vs NMJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/58/10155\" title=\"table 13\">",
"      Motor exam score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7676\" title=\"table 14\">",
"      Lumbosacral radiculopathy symptoms signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/23/8571\" title=\"table 15\">",
"      Reflex exam score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/33/40477\" title=\"table 16\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/36/37451\" title=\"table 17\">",
"      Lacunar syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27848?source=related_link\">",
"      Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=related_link\">",
"      Homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/63/34807?source=related_link\">",
"      Locked-in syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42138?source=related_link\">",
"      Medical care of the nursing home patient in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14137?source=related_link\">",
"      Myopathies of systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41688?source=related_link\">",
"      Overview of neuromuscular junction toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=related_link\">",
"      Tick paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_58_27563="ART for PEP after nonoccupational exposure to HIV";
var content_f26_58_27563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antiretroviral regimens postexposure prophylaxis following a nonoccupational exposure to HIV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preferred regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine (Truvada) plus raltegravir (Isentress)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternative regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine (Truvada) plus ritonavir-boosted atazanavir (Reyataz)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine (Truvada) plus ritonavir-boosted darunavir (Prezista)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional possible regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rilpivirine-tenofovir-emtricitabine (Complera)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir-emtricitabine (Truvada) plus lopinavir-ritonavir (Kaletra)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Lamivudine-zidovudine (Combivir) can be substituted for tenofovir-emtricitabine in situations in which tenofovir is contraindicated, eg, chronic renal insufficiency. These are recommendations of the authors and consistent with the 2012 United States DHHS guidelines for treatment of HIV-infected adults.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Available at file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. Accessed 28 March 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27563=[""].join("\n");
var outline_f26_58_27563=null;
var title_f26_58_27564="Infant hip imaging overview";
var content_f26_58_27564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Use of various imaging modalities in the evaluation and management of selected hip problems in infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Conventional arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Developmental dysplasia of the hip",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Diagnosis in children &gt;4 months",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Superolateral displacement of the femur",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Evaluation of infants &lt;4 months who are high risk or have equivocal clinical findings",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Superolateral displacement of the femoral head",
"         </li>",
"         <li>",
"          Alpha angle less than 60 degrees",
"         </li>",
"         <li>",
"          Instability of hip (able to move in and out of socket)",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Preoperative assessment",
"       </td>",
"       <td>",
"        Preoperative assessment",
"       </td>",
"       <td>",
"        Intraoperative confirmation of femoral head position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitoring treatment",
"       </td>",
"       <td>",
"        Postoperative follow-up",
"       </td>",
"       <td>",
"        Evaluation of postsurgical reduction",
"       </td>",
"       <td>",
"        Intraoperative visualization of structures interfering with reduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow-up of patients treated with abduction splints (eg, Pavlik harness)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Monitoring for long-term sequelae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Proximal femoral focal deficiency",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Diagnosis",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Short femur with dysmorphic or absent head and neck",
"         </li>",
"         <li>",
"          Delayed appearance or non-appearance of the femoral capital ossification center",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Early diagnosis, extent of involvement",
"        </p>",
"        Findings:",
"        <br/>",
"        <ul>",
"         <li>",
"          Incompletely ossified femoral head",
"         </li>",
"         <li>",
"          Demonstrates cartilage structure of acetabulum and upper femur",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27564=[""].join("\n");
var outline_f26_58_27564=null;
var title_f26_58_27565="Relationship between fetal pH and BPS";
var content_f26_58_27565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The relationship between fetal umbilical venous pH (&plusmn;2 SD) by cordocentesis and the fetal biophysical profile score (BPS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correlation was linear, inverse, and very significant (R",
"    <sup>",
"     2",
"    </sup>",
"    0.912; P&lt;0.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data published in: Manning, FA. Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score. Clin obstet Gynecol 1995; 38:26.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27565=[""].join("\n");
var outline_f26_58_27565=null;
var title_f26_58_27566="Modified NCI CTCAE v4 grading radiation dermatitis";
var content_f26_58_27566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed modifications to the NCI-CTCAE v4.03 grading and grade-specific management strategies for patients developing radiation dermatitis during treatment with cetuximab plus radiotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Grade 1",
"        </strong>",
"        *",
"        <strong>",
"         :",
"        </strong>",
"        Faint erythema or dry desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          General management approaches",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Weekly follow-up is adequate, unless rapid progression is noted",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Grade 2",
"        </strong>",
"        *",
"        <sup>",
"         &loz;",
"        </sup>",
"        <strong>",
"         :",
"        </strong>",
"        Moderate to brisk erythema and/or dry desquamation; patchy moist desquamation, or nonhemorrhagic crusts mostly confined to skin folds and creases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          General management approaches",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Consider twice-weekly assessments to monitor for rapid change",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Dry desquamation without crusts:",
"        <br/>",
"        <ul>",
"         <li>",
"          Consider glucocorticosteroid cream or ointment for a limited period (one to two weeks)",
"         </li>",
"         <li>",
"          Consider topical antiseptics and antibiotics for the prevention of more severe reaction",
"         </li>",
"         <li>",
"          Topical antiseptics and antibiotics at any sign of superinfection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Moist desquamation in skin folds:",
"        <br/>",
"        <ul>",
"         <li>",
"          Topical antiseptic",
"         </li>",
"         <li>",
"          Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks)",
"         </li>",
"         <li>",
"          Topical antibiotics active against S. aureus at any sign of superinfection; consider systemic antibiotics if superinfection becomes more severe",
"         </li>",
"         <li>",
"          Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds, but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems. Topical eosin in skin folds or on erosive lesions may also be a useful treatment approach.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Dry desquamation with isolated non-hemorrhagic crusts:",
"        <br/>",
"        <ul>",
"         <li>",
"          Topical antiseptic",
"         </li>",
"         <li>",
"          Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks)",
"         </li>",
"         <li>",
"          Topical antibiotics active against S. aureus at any sign of superinfection. Consider systemic antibiotics if superinfection becomes more severe.",
"         </li>",
"         <li>",
"          Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems.",
"         </li>",
"         <li>",
"          Hydrogels can be used to keep crusts flexible",
"         </li>",
"         <li>",
"          Consider debridement using hydrogels; skin trauma should be avoided to prevent superinfection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Grade 3",
"        </strong>",
"        *",
"        <sup>",
"         &loz;",
"        </sup>",
"        <strong>",
"         :",
"        </strong>",
"        Moist desquamation or hemorrhagic crusts; nonhemorrhagic crusts other than in skin folds and mostly confined to skin folds and creases; bleeding induced by minor trauma or abrasion; superinfection requiring oral antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          General management approaches",
"          <sup>",
"           &loz;",
"          </sup>",
"         </li>",
"         <li>",
"          Evaluate the need for daily assessment",
"         </li>",
"         <li>",
"          Closely monitor for signs of local or systemic infection",
"         </li>",
"         <li>",
"          For grade 3 reactions occurring at &lt;50 Gy, consider brief interruption in treatment",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Confluent moist desquamation without crusts:",
"        <br/>",
"        <ul>",
"         <li>",
"          Topical antiseptic",
"         </li>",
"         <li>",
"          Consider adding daily topical glucocorticosteroid lotion to reduce inflammation for a limited period (one to two weeks)",
"         </li>",
"         <li>",
"          Topical antibiotics active against S. aureus at any sign of superinfection",
"         </li>",
"         <li>",
"          If superinfection becomes more severe, consider the use of IV antibiotics if unresponsive to oral antibiotics",
"         </li>",
"         <li>",
"          Topical eosin or soft zinc preparations in the skin folds. A thin layer of a soft zinc preparation may be used in skin folds, but should be removed before treatment with radiotherapy to avoid radiation dosimetric problems. Topical eosin in skin folds or on erosive lesions may also be a useful treatment approach.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Confluent moist desquamation with crusts:",
"        <br/>",
"        <ul>",
"         <li>",
"          Topical antiseptic",
"         </li>",
"         <li>",
"          If superinfection becomes more severe, consider the use of IV antibiotics if unresponsive to oral antibiotic",
"         </li>",
"         <li>",
"          Consider debridement using hydrogels; skin trauma should be avoided to prevent superinfection",
"         </li>",
"         <li>",
"          If hydrocolloid dressings are used, the thickness of the dressing should be taken into account for the radiotherapy dosimetry; hydrofiber dressings can be used after completion of radiotherapy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Grade 3",
"        </strong>",
"        <sup>",
"         *&loz;",
"        </sup>",
"        <strong>",
"         :",
"        </strong>",
"        Life-threatening consequences; extensive confluent hemorrhagic crusts or ulceration (&gt;50 percent of involved field); extensive spontaneous bleeding from involved site (&gt;40 percent of the involved site); skin necrosis or ulceration of full-thickness dermis or any size ulcer with extensive destruction, tissue necrosis or damage to muscle, bone or supporting structures with or without full-thickness skin loss",
"        <sup>",
"         &sect;",
"        </sup>",
"        ; skin graft indicated; ulceration associated with extensive superinfection with IV antibiotics indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          General management approaches",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Consider interrupting treatment with both radiotherapy and cetuximab; cetuximab should be interrupted until the skin reaction has resolved to at least grade 2",
"         </li>",
"         <li>",
"          In the case of severe superinfection, consider IV antibiotics if unresponsive to oral antibiotics",
"         </li>",
"         <li>",
"          Hospitalize the patient",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based upon modified National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE)",
"     <br>",
"      &Delta; General management approach: Patients should be provided with written information on how to manage skin reactions. Patients should keep the affected skin clean, wash their hands before touching the affected area, and use clean towels. The affected area should be washed once in the morning and once in the evening, using pH 5 (pH skin neutral) soaps and/or showering oils for sensitive skin, followed by moisturization with an unperfumed moisturizer recommended for dry skin. There is no evidence of any benefit of aloe vera and it may aggravate the reaction to treatment. Moisturizers that contain urea (&lt;3 percent) and/or have a high glycerol content are recommended. Shaving with a sharp, disinfected wet razor should be encouraged to reduce the risk for folliculitis; care should be taken to avoid local trauma. Patients should avoid sunbathing/sun exposure, scratching and mechanical trauma, and the use of skin irritants such as alcohol-based lotions and perfumes. Debridement of crusts may reduce the risk for superinfection and bleeding and may help pain management. Local trauma should be avoided. Hydrogels can be used to keep crusts flexible and reduce the risk for skin trauma and pain as well as to facilitate debridement. Following debridement, emollients can be used to moisturize the skin, and/or hydrocolloid or hydrofiber dressings can be used to protect the skin from further trauma. All dressings should be transparent, so that signs of superinfection can be observed. Care should be taken to ensure that anything used on the skin (eg, dressings or creams) does not alter the dose of radiation. The patient should be closely monitored for signs of systemic inflammatory response and changes in the clinical presentation of dermatitis. Where superinfection is suspected in cases of dermatitis up to grade 2, local antiseptics and/or topical antibiotics may be beneficial. The use of systemic antibiotics may be considered if superinfection becomes more severe. Before the initiation of any antibiotic treatment, cultures should be obtained.",
"      <br>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       Possibility of local superinfection as indicated by the clinical appearance (moist desquamation and crusts, with yellowing) and by microbiological assessment (from swabs of the area and blood tests); suspected systemic superinfection is indicated by the presence of at least two of the following four variables of systemic inflammatory response syndrome: fever with a core temperature &gt;38&deg;C or &lt;36&deg;C, heart rate &gt;90 beats per min, respiratory rate &gt;20 breaths per min, leukocytosis (&gt;12 x 10",
"       <sup>",
"        9",
"       </sup>",
"       /l) or leukopenia (&lt;4 x 10",
"       <sup>",
"        9",
"       </sup>",
"       /l).",
"       <br>",
"        &sect; Skin necrosis of full-thickness dermis is rarely seen with the recommended doses of cetuximab plus radiotherapy and this type of diagnosis should be based only on a biopsy of tissue from the involved site.",
"        <br/>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiveing cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and concensus managment guidelines. Ann Oncol 2011; 22:2191, by permission of Oxford University Press. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27566=[""].join("\n");
var outline_f26_58_27566=null;
var title_f26_58_27567="Pavlik harness";
var content_f26_58_27567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pavlik harness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Pavlik harness is a dynamic splint that prevents hip extension and adduction, but permits flexion and abduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_58_27567=[""].join("\n");
var outline_f26_58_27567=null;
